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RSV remains one of the leading causes worldwide of acute lower respiratory tract 
infections. Despite continued effort, no vaccine exists and prophylaxis is limited to high-
risk populations due to cost and limited efficacy of broadly neutralizing antibodies. 
Additionally, much of the general biology surround RSV replication and assembly is 
incomplete. The overall goal of the work presented here was to identify: 1) new targets for 
RSV therapeutics by analyzing RSV filament assembly (structures critical to high RSV 
titers), and 2) novel prophylactics against RSV to prevent infection. First, we developed a 
live-cell labeling method using a lectin, a class of proteins that bind specific glycan 
moieties, specific for RSV G. SBA was found to not inhibit the infectivity or replication of 
RSV by several metrics. We observed the first live images of RSV filament formation using 
this labeling technique, and critically, we found that this process can occur prior to the 
plasma membrane (where RSV was originally thought to assemble). This technique was 
then utilized to find that filament formation is microtubule and, specifically, dynein 
mediated. We also discovered that the loading of RSV genome into extended filaments is 
a microtubule-mediated process. We used synthetic, modified mRNA to express 
engineered broadly neutralizing antibodies to prevent RSV infection. We developed the 
use of both secreted and membrane-anchored palivizumab that prevents RSV infection in 
vitro and in the lungs of mice. We showed that encoding a membrane anchor on the 
antibodies prevents the antibody from diffusing away from the cell and blocks viral 
particles from entering the cell. Finally, the membrane-anchor was adapted to a highly 
potent RSV-neutralizing single-domain camelid antibody. The anchored VHH prevented 










Respiratory syncytial virus incidence and current therapeutics 
  
Human respiratory syncytial virus (RSV) remains the leading cause of acute lower 
airway infections in children1. Annually, there are 33.1 million RSV cases globally in 
children under the age of 5, resulting in more than 3.2 million hospitalizations1. Despite 
the large worldwide burden of RSV, no effective vaccine yet exists2. 
To date, the only FDA-approved preventative therapeutic for RSV infection is 
Synagis produced by MedImmune, known formally as palivizumab. Palivizumab is a 
humanized monoclonal antibody that neutralizes RSV virion. Palivizumab is traditionally 
only given to immunocompromised children due to high cost, required monthly doses 
throughout the RSV season, and limited effectiveness. While palivizumab is fairly potent 
when used to inhibit RSV infection in animal models, it only reduced RSV hospitalization 
rate of infants of 29-32 week gestation from 5.0% to 3.1%3,4. The observed limited efficacy 
is likely due to the route of delivery of the antibody. Typically, palivizumab is delivered by 
intramuscular (IM) injection, and the antibody must diffuse into the bloodstream, travel to 
the lungs, and diffuse into the bronchoalveolar space before it can bind and inhibit RSV 
infection. The largest decrease in palivizumab concentration occurs in this last step, where 
the antibody must diffuse out of the bloodstream and into the airways of the lungs, with 
BAL titers dropping nearly 2000-fold from serum levels at 4 days post infection5. 
In immunocompromised individuals infected with RSV, Ribavirin, a purine analog, 
is the only FDA approved antiviral. A recent study indicated that oral delivery of Ribavirin 
is also effective, reducing cost and inconvenience6. However, in the vast majority of 




 RSV taxonomy, structure, and life cycle 
 
RSV belongs to the order Mononegavirales, family Paramyxoviridae, subfamily 
Pneumovirinae, and genus Pneumovirus; in humans, RSV is further subdivided into 
antigenic subgroups A and B. As such, the RSV virion has a pleomorphic morphology 
containing a non-segmented single-stranded negative-sense RNA genome. This genome 
contains 10 genes encoding for 11 proteins. These include the fusion glycoprotein (F), the 
major/attachment glycoprotein (G), the viroporin (SH), the nucleoprotein (N), the 
phosphoprotein (P), the RNA-dependent RNA polymerase (L), two nonstructural proteins 
(NS1 and NS2), the matrix protein (M), and two M2 variants that are alternate reading 
frames of the M2 gene (M2-1 and M2-2)7.  
RSV F is one of three encoded glycoproteins (alongside RSV G and SH) and is 
necessary for viral fusion with the cellular membrane and subsequent entry into host cells. 
Once virions are internalized, the RSV L, along with RSV N and P, transcribes viral 
genomic RNA into mRNA, which encode viral proteins. Viral transmembrane proteins are 
post-translationally glycosylated and transported by the secretory membrane system to 
the plasma membrane, where they interact with ribonucleoprotein (RNP) complexes 
consisting of RSV N, RSV P, potentially RSV M, and viral genomic RNA8,9. The virus then 
assembles into mature pleomorphic particles which are either spherical or filamentous10,11.  
RSV filament formation 
 
Formation of RSV filaments, which contributes to higher viral titers, requires RSV 
F, RSV N, RSV P, and RSV M, potentially through their contribution to cell to cell spreading 
of the virus12–15.  Several studies demonstrated that the RSV M dimerizes and binds to the 
cytoplasmic tail of RSV F, and thus plays a major role in the production of filamentous 
virions16,17. RSV M also appears to be responsible for the maturation and elongation of 
RSV filaments18. Additionally, RSV M has been shown to assemble into filamentous 
structures in vitro19.  Even though there has been significant emphasis on the roles of RSV 
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F and M during filament formation, the steps leading to filament assembly are not clear. 
Some reports hypothesized that RSV might utilize a second maturation pathway, where 
virions bud into intracellular vesicles forming filaments, but these findings have not been 
confirmed or further investigated20,21.  
A variety of host-cell factors, particularly cytoskeleton components, have been 
implicated in RSV filament formation, however, our understanding of their mechanistic role 
is limited. Both ß-actin and actin-associated proteins were found in sucrose gradient-
purified RSV preparations22. Additionally, actin was found to be primarily involved with 
virion egress, but has also been implicated in filament production23,24. Indeed inhibition of 
RhoA, an actin modulatory kinase, results in a shift to more spherical virion morphologies, 
and disruption of the actin network, which also leads to halting of RSV filament motion13,25. 
Microtubules have also been shown to play a key role in the assembly of progeny RSV23. 
In contrast, other groups have suggested that filaments can form independently of the 
host-cell cytoskeleton12. 
Current RSV filament imaging techniques 
 
Previous studies have investigated the various viral and cellular components 
necessary generate viral filaments10,12,17,18,26–28. The majority of these studies completed 
their work in fixed cells and were unable to analyze the dynamics of filament assembly as 
it was occurring. To date, two studies of viral filament dynamics on live cells have been 
performed25,26. The imaging of RSV filament dynamics using molecular beacons by 
Santangelo et al. gave insight into the flexibility and motion of viral filaments, but only after 
they had formed25. Additionally, RSV filament formation was studied live on caveolar 
membranes, providing useful insights on the role of endocytic proteins in filament 
formation26. However, this imaging was performed indirectly using fluorescent caveolin as 





Clearly, there exists a need for novel therapeutics to prevent and treat RSV. 
Therefore, the overarching goals of this thesis were to: 1) investigate the basic biology of 
RSV filament assembly, much of which is still unknown, and 2) engineer new therapeutics 
to prevent RSV infections. To accomplish these goals, three aims were originally 
proposed: 
1. Characterize the mechanisms governing RSV filament formation by labeling 
RSV G with lectins in live infected cells. 
2. Develop gold-conjugated lectins to enable high-resolution RSV G localization 
studies using cryo-electron microscopy (cryoEM). 
3. Prevent the fusion of RSV in a murine model using intra-tracheal aerosol 
delivery of IVT mRNA encoding membrane-anchored neutralizing antibodies. 
The work of this thesis completed the first and third aims (Chapters 2 and 3, respectively), 
and several steps were taken to complete the second aim, detailed in Chapter 4. First, 
conjugation of lectins to gold nanoparticles was checked with HPLC and darkfield imaging. 
Additionally, cryoEM necessitates a maximum sample thickness of 500-700 nm29. 
Because of this, cells must be plated very sparse, which can affect both cell and viral 
growth. To combat this, cell monolayers were infected for 24 h before being lifted into 
suspension using trypsin, and the infected cells were plated at lower confluency. 
Additionally, due to the strict maximum thickness requirement, thin cell lines (less than 
500-700 nm thick on the edges of the cell) must be chosen for study using cryoEM. 
Because glycosylations can vary dramatically between different cell lines, the lectins used 
for study were assessed on Beas2B and A549 cells, both used extensively in RSV EM 
research30. Finally, if cryoEM is not feasible for any reason, direct stochastic optical 
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reconstruction microscopy (dSTORM), a super-resolution localization imaging technique, 
was tested as an alternative. 
Imaging modalities 
 
In this thesis, several imaging techniques were utilized which will be briefly 
described. The live-cell imaging performed in the studies presented here (and many of the 
fixed-cell experiments) was completed using a spinning disk confocal microscope. 
Spinning disk confocals afford a very fast frame rate with minimal out-of-focus light, but 
are still limited to, at best, 180 nm lateral and 500 nm axial resolution due to the diffraction 
of light31. To obtain sub-diffraction limited images of RSV in future work, we will turn to 
either EM (or cryoEM), or dSTORM. EM involves using a high-intensity electron beam 
(with a much smaller diffraction limit than visible light) as an illumination source, with 
electron-dense particles, such as gold, to enhance contrast. Because EM requires intact 
cellular ultrastructure, strong chemical fixatives are used in the staining process. These 
fixatives can alter structures and introduce artifacts that must be addressed when making 
biological conclusions32. CryoEM aims to eliminate these artifacts by flash freezing a 
biological sample to preserve the native structures, and can achieve resolutions on the 
order of single angstroms33. However, as mentioned previously, CryoEM has very strict 
requirements for cell thicknesses. Finally, dSTORM uses high power lasers alongside 
chemically modified buffers, which create an anoxic environment to deactivate and 
reactivate fluorophores34. The centroids of these individual “blinks” are then found, 
calculated, and the software reconstructs the image after several thousand frames are 
collected. This results in an improved axial resolution of approximately 20 nm over the 200 
nm resolution of diffraction limited confocal microscopy.  
Safety of therapeutic mRNA compared to virus and DNA  
 
Several DNA based therapeutics have been evaluated in preclinical and clinical 
trials, however, thus far, no DNA based product has been approved for human use. There 
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are several contributing factors responsible for this delay, the most critical of which is 
safety. DNA is a pathogen associated molecular pattern that activates the innate immune 
response by triggering intracellular DNA pattern recognition receptors (PRRs), thereby 
initiating the interferon signaling pathway35–38. While mRNA therapeutics can also be 
sensed by endosomal and cytosolic PRRs, using chemically modified bases during the in 
vitro transcription process can mask the mRNA from these sensors. Use of DNA 
therapeutics also provokes concerns of integration into the host genome, and while this 
effect has been found to be minimal so far, potential integration must continue being 
monitored for each antigen expressed by the DNA39,40. Although single-stranded mRNA 
recombination is possible in rare circumstances, mRNA never interacts directly with the 
genome41,42. Additionally, studies indicate that anti-DNA antibodies are typically produced 
in response to vaccination by DNA, but are not expressed in sufficient quantity or duration 
to cause disease43,44. Finally, the vehicle used for nucleic acid delivery can invoke either 
an immune response or inflammatory toxicity or both45–48. While this effect is desirable in 
the case of vaccination against the encoded antigen, eliciting an immune response can 
inhibit expression of directly therapeutic proteins not intended to produce long-term 
immunity. Moreover, multiple studies have shown that detectable expression from naked 
mRNA is possible and that more protein is produced during peak expression than naked 
plasmid DNA49–51. 
One method of efficiently delivering nucleic acid based therapies is to use modified 
viruses. Although several viral families have been studied for gene therapy application, 
adeno-associated viruses (AAV) are the most prominent, in part due to being replication 
deficient and minimally pathogenic52–54. Microarray studies have shown that AAV vectors 
are weak activators of the innate immune system and do not invoke a strong type I 
interferon (IFN) response55. However, because AAV and other viral vectors do elicit an 
adaptive immune response against the virus, consecutive dosing is a nontrivial hurdle56–
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58. While the majority of vaccines are given through consecutive doses, a memory immune 
response against AAV would limit the ability to do so and not allow for other immunizations 
using AAV vectors. Additionally, since humans are a natural host for AAV, large portions 
of the population have neutralizing antibodies against subtypes of the virus: from 30 to 
70% of the population in the case of AAV type 2 down to 15 to 35% of the population for 
AAV type 859,60. While AAV vectors are efficient and safe delivery agents of nucleic acids, 
their use is limited to a single dose and they are ineffective for a large portion of the 
population that has pre-existing immunity. 
As mentioned above, mRNA has several distinct advantages over DNA as a gene 
transfer modality. Specifically, mRNA expression is: 1) safer due to its transient expression 
and localization apart from the genome, 2) more rapid due to only needing to enter the 
cytosolic compartment before expression can begin, and 3) can often transfect cells that 
are difficult to transfect with DNA. However, cellular PRRs in the innate immune response 
system have adapted to detect exogenous mRNA as a response to microbial infection61–
64. This detection can result in upregulation of proinflammatory cytokines and PKR (Protein 
kinase R) activation, which can lead to translational arrest and reduced protein 
expression65. The most common and, currently, efficient method of evading PRR 
activation is substituting one or more of the RNA bases for chemically modified 
nucleosides66,67. In our work, we linearize a plasmid DNA template encoding the mRNA 
sequence using restriction enzymes followed by IVT with a T7 mScript kit (Cellscript) and 
ATP, GTP, CTP, and N1-methyl-pseudouridine-5’-triphosphate (m1Y).  
Rapid expression of mRNA delivered therapeutics 
 
In addition to being safer than DNA for human therapeutic use, mRNA also 
produces protein faster than DNA51,68. This is predominately due to two factors: 1) DNA 
requires translocation into the nuclear envelope, which is an inefficient and slow process 
compared to cytosolic delivery, and 2) transcription is required before protein can be 
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produced from DNA, while mRNA can be translated as soon as it is presented in the 
cytosol.  
Potential for simple, inexpensive, off-the-shelf protection 
 
Live-attenuated and inactivated vaccines, as well as nanoparticles and 
lipoparticles, often require refrigeration or freezing for storage and transport. Naked 
nucleic acid therapeutics have no such limitation. Both DNA and mRNA can readily be 
lyophilized and shipped and stored at ambient temperature with minimal degradation, 
especially if kept under sealed anhydrous and anoxic conditions69. The therapeutic nucleic 
acid can then be briefly rehydrated in water before being delivered to the individual. 
Previous applications of mRNA therapeutics in the lung 
 
To date, expression of therapeutic proteins from mRNA in the lung has been used 
to treat a variety of diseases in vivo. First, expression of surfactant protein B (SP-B) in the 
lungs of congenital SP-B deficient mice increased hematocrit and survival rates in 
transfected mice70. However, the nature of mRNA means that this protein expression is 
only transient, and as such using mRNA to encode congenital deficiencies is not a long-
term solution. To combat this, researchers have used mRNA to transiently express site-
specific nucleases to alter the genome of transfected cells in the lungs of SP-B deficient 
mice, prolonging their life71. Additionally, therapeutic proteins to successfully alleviate 
allergic responses have also been delivered by aerosolized mRNA into the lungs of mice72. 
Together, these studies demonstrate that mRNA expression of therapeutic proteins in the 
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The work presented here is from Vanover D, Smith DV, Blanchard EL, Alonas E, 
Kirschman JL, Lifland AW, Zurla C, Santangelo PJ. “RSV glycoprotein and genomic RNA 
dynamics reveal filament assembly prior to the plasma membrane.” Nature 
Communications (2017, doi:10.1038/s41467-017-00732-z).  
Background 
 
Respiratory syncytial virus (RSV) remains the leading cause of acute lower 
respiratory infections worldwide in children under five years of age and leads to roughly 3 
million hospital admissions each year73. Despite the high global incidence rate of infected 
patients, no effective vaccine yet exists2. While various treatments are being actively 
investigated, the cellular events that occur during RSV assembly are poorly understood.   
RSV is a member of the Paramyxoviridae family and contains a single-stranded 
negative-sense RNA genome that encodes for 11 proteins. The RSV fusion protein (RSV 
F) is one of three encoded glycoproteins and is necessary for viral fusion with the cellular 
membrane and subsequent entry into host cells. Once virions are intracellular, the large 
(RSV L) polymerase, working with the RSV nucleoprotein (RSV N), and phosphoprotein 
(RSV P), transcribes viral genomic RNA into mRNA, which encode viral proteins . Viral 
transmembrane proteins are post-translationally glycosylated and transported by the 
secretory membrane system to the plasma membrane, where they interact with 
ribonucleoprotein (RNP) complexes consisting of RSV N, RSV P, potentially RSV matrix 
protein (RSV M), a structural protein, and viral genomic RNA8,9. The virus then assembles 
into mature pleomorphic particles which are either spherical or filamentous10,11. Formation 
of these filaments requires RSV F, RSV N, RSV P, and RSV M, and has been found to 
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contribute to higher viral titers, potentially through their contribution to cell to cell spreading 
of the virus12–15.  Some reports hypothesized that RSV might utilize a second maturation 
pathway, where virions bud into intracellular vesicles forming filaments, but these findings 
have not been confirmed or further investigated20,21. Several studies demonstrated that 
the RSV M dimerizes and binds to the cytoplasmic tail of RSV F, and thus plays a major 
role in the production of filamentous virions16,17. RSV M also appears to be responsible for 
the maturation and elongation of RSV filaments18. Additionally, RSV M has been shown 
to assemble into filamentous structures in vitro19.  Even though there has been significant 
emphasis on the roles of RSV F and M during filament formation, the steps leading to 
filament assembly are not clear.  
A variety of host-cell factors, particularly cytoskeleton components, and viral 
proteins have been implicated in RSV filament formation, however our understanding of 
their mechanistic role is limited. Both ß-actin and actin-associated proteins were found in 
sucrose gradient-purified RSV preparations22. Additionally, actin was found to be primarily 
involved with virion egress, but has also been implicated in filament production23,24. 
Indeed, inhibition of RhoA, an actin modulatory kinase, results in a shift to more spherical 
virion morphologies, and disruption of the actin network, which also leads to halting of 
RSV filament motion13,25. Microtubules have also been shown to play a key role in the 
assembly of progeny RSV23. In contrast, other groups have suggested that filaments can 
form independently of the host-cell cytoskeleton12.  
 The viral G protein is a highly glycosylated 90 kDa transmembrane protein, 
primarily responsible for the attachment of RSV to the host cell 74–76. Though not required 
for the production of infectious RSV or virus-like particles, RSV G is necessary for full 
infectivity and is found on the membrane of mature filaments 21,77,78. Additionally, RSV G 
interacts with both RSV M and F protein, which appears to be required for complete virion 
assembly 79,80.  During initial virus entry, RSV glycoproteins have been shown to internalize 
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via clathrin-mediated endocytosis,  whereas caveolin is heavily incorporated into the 
envelope of mature RSV filaments 26,81–83. RSV G was also found to be cleaved in the Vero 
cell line during endosomal recycling, and has been implicated in the maturation and egress 
of RSV8,10,82,84 . While the RSV G glycoprotein is found within progeny viral filaments and 
is clearly essential for virion entry into host cells, little data exists on the dynamics or 
trafficking of RSV G during infection, due to a lack of available reagents for tracking RSV 
G in live cells85.  
Previously, we have demonstrated the use of single molecule sensitive RNA 
probes for imaging RSV viral genomic RNA in live cells, but the lack of a method for 
tracking the viral transmembrane proteins precluded our ability to image viral particle 
formation.  In order to target the G protein, we investigated the use of the lectin soybean 
agglutinin (SBA) for specific labeling of RSV G, and found that SBA binding did not affect 
RSV infectivity, replication, or formation of viral filaments. Using fluorescently-conjugated 
SBA, we report here that membrane bound RSV G recycles from the plasma membrane 
via clathrin-mediated endocytosis into vesicles. We also show that these recycling 
endocytic vesicles merge with intracellular vesicles containing viral genomic RNPs and 
eventually associate with caveolin before returning to the plasma membrane. To the best 
of our knowledge, this is the first live imaging of a wild-type RSV viral protein (RSV G) and 
genomic RNA during RSV filament formation which revealed: the dynamics of filament 
formation, the production of branched filamentous structures typical of late-stage 
infections, the importance of microtubules in the assembly and loading of these 
filamentous structures in the cytosol, and the halting of this rapid motion once these 
structures merge with the plasma membrane. Together, these results change our 
understanding of RSV filament assembly and loading prior to the membrane and open 
new avenues for research and RSV therapeutics.  
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Fluorescent SBA conjugates specifically bind RSV G 
 RSV G was previously found to contain N-acetylgalactosamine (GalNAc) side 
chains, which interact specifically with various lectins86. We first analyzed the localization 
of Alexa Fluor 488 conjugated SBA (SBA-488) in cells infected with the A2 strain of human 
RSV with respect to RSV G and RSV F. Immediately prior to infection, SBA was delivered 
to cells at 4 °C, in order to minimize non-receptor mediated endocytosis. Upon infection 
for 24 hours, both RSV G and RSV F colocalized with SBA-488, with minimal background 
in mock-infected controls (Figure 2.1A). In addition, the SBA-488 signal in both the 
membrane and filaments was higher in infected cells than in control cells (Figure 2.1B), 
which indicated that a large portion of glycoprotein was present in the membrane (Figure 
2.1A). Due to previous reports describing the binding of RSV F and RSV G in solution, we 
opted to examine a reduced system, using microscopy and expression of individual viral 
proteins, instead of an immunoprecipitation assay to demonstrate the specificity of SBA 
for RSV G87. Vero cells were transfected with in vitro transcribed (IVT), modified mRNA 
that encodes for either RSV F or RSV G88. We then labeled the cells with SBA-488 before 
fixing and immunostaining, without permeabilization, for RSV F and G (Figure 
2.1C).  While transfection with RSV F did not alter background SBA staining, cells 
transfected with RSV G showed a marked increase in SBA staining relative to 
untransfected control cells, due to the heavy glycosylation of the RSV G protein. SBA 
colocalized in cells transfected with RSV G and not with RSV F, as indicated by both the 
Pearson’s correlation coefficient and Mander’s colocalization coefficient (Figure 2.1D). A 
Pearson’s correlation value much greater than 0 indicates a significant positive correlation 
between RSV G and SBA. The significantly higher Mander’s coefficient indicates that a 
much larger percentage of the RSV G signal contains SBA signal, while very little of the 
RSV F signal contains SBA. The expressed RSV G and RSV F both localized to the 
plasma membrane, evidenced by the distribution of the viral proteins across the cell 
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(Figure 2.1C) and by the layer of protein occupying a higher imaging plane than the nuclei 
of the cells (Figure 2.1E). Overall, these results indicate that SBA can be used to 





Figure 2.1. SBA selectively binds RSV G. (A) Vero cells infected (top) or mock-infected 
(bottom) for 24 h with RSV A2 at an MOI of 1 were labeled with SBA-488 at 4 ºC (green) 
before being fixed and stained for RSV G (red), RSV F (blue), and nuclei (gray). Extended 
focus image is shown. Scale bar represents 10 µm. (B) Enlarged cropped images from 
the white boxed regions from part (A) with intensity profiles showing colocalization along 
the direction of the white arrow. Scale bar represents 1 µm. (C) Cells transfected for 24 h 
with RSV G (top) and RSV F (bottom) mRNA were labeled with SBA-488 at 4 ºC (green) 
before being fixed and stained without permeabilization for RSV G or RSV F (red) and 
nuclei (gray). Extended focus image is shown. Scale bar represents 15 µm. (D) Mander’s 
colocalization coefficient and Pearson’s correlation between RSV G or RSV F and SBA. 
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Dotted line indicates 0 correlation. n=16 cells per group. Error bars represent 95% 
confidence interval. Asterisks indicates p<0.0001 by Mann-Whitney U Test. (E) Enlarged 
cropped images from the white boxed regions from part (C) with YZ cross-sections (left). 
Intensity profiles, indicated by the white line on the YZ cross-section, show the expressed 
RSV protein on a higher plane than the nucleus as indicated by the arrow. Extended focus 




SBA conjugates do not inhibit replication of RSV 
We subsequently verified that SBA does not alter RSV replication or infectivity. 
First, we labeled RSV A2 virus stocks with SBA-488. Then, we isolated the filamentous 
and spherical viral particles and deposited them onto glass coverslips as described 
previously 11. Using fluorescence imaging and colocalization analysis, we verified that SBA 
was bound to both filamentous and spherical particles, which also contained RSV F and 
RSV N (Figure 2.2A). Note that RSV infected cells generate incomplete and complete 
virions, as indicated by particles that contain only some of the various viral proteins11. To 
demonstrate that labeling RSV A2 with SBA-488 did not significantly inhibit viral 
replication, we infected cells for 24 h and stained for RSV F and RSV N (Figure 2.2B). 
Both cytosolic IBs and viral filaments were found, indicative of late-stage infections.  
We then sought to determine the effect of SBA-labeled RSV A2 on virus infectivity. 
First, we bound SBA to RSV A2, similarly to assays described previously89. We then 
infected cells and measured RSV G protein synthesis relative to unlabeled RSV A2 after 
12 and 24 hours via western blot (Figure 2.2C). Both the untreated and SBA-treated 
lysates contained similar amounts of RSV G at both time points. We quantified the 
amounts of protein using densitometry, and found that the differences at either time point 
were not statistically significant (Figure 2.2D). To further test whether SBA affects RSV 
infectivity, we incubated RSV virus modified to express recombinant green fluorescent 
protein (rgRSV-GFP) with either palivizumab or SBA and measured GFP signal via flow 
cytometry90,91. Because rgRSV-GFP has reduced permissivity compared to RSV A2, we 
allowed the infection to proceed for 48 h, before assaying the cells for GFP signal. SBA-
labeled rgRSV-GFP or unlabeled virus infected a similar percentage of cells, while 
palivizumab-labeled virus abrogated any productive infection (Figure 2.2E).  Last, we 
compared via qRT-PCR the levels of RSV N and G mRNA at 6, 12, and 24 h post-infection 
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(hpi) with SBA-labeled RSV and unlabeled RSV, and found no statistically significant 






Figure 2.2. SBA binding does not inhibit RSV binding or replication. (A) SBA-488 
(green) was incubated with RSV A2 stocks for 30 min before filaments were isolated onto 
glass coverslips. Isolated virions were fixed and stained for RSV N (red) and RSV F (blue). 
Scale bar represents 2 µm. (B) SBA-488 labeled virus (green) was used to inoculate Vero 
cells at an MOI of 1. At 24 hpi, cells were fixed and immunostained for RSV N (red), RSV 
F (blue), and nuclei (gray). Scale bar represents 10 µm. (C) RSV A2 was incubated with 
either SBA or vehicle control for 2 h at 37 ºC. Virus was then used to inoculate Vero cells 
at an MOI of 1. At 12 or 24 hpi, cells were lysed, and lysates were assayed by western 
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blotting for RSV G. ß-actin is included as a loading control. Image is representative of two 
independent experiments. (D) Replicate lanes were quantified by densitometry to compare 
the amount of RSV G signal from SBA-labeled or unlabeled RSV infections. There were 
no statistically significant differences at either time point (two-way ANOVA, p>0.05). (E) 
rgRSV-GFP was incubated with the indicated concentrations of either palivizumab, SBA, 
or vehicle control for 2 h at 37 ºC. Virus treatments and a mock treatment were then used 
to inoculate Vero cells at an MOI of 1. At 48hpi cells were lifted into a single-cell 
suspension and analyzed by flow cytometry. Data represents the mean percentage of 
infected cells in three independent experiments. Error bars represent standard deviation. 
Asterisk indicates significanct difference versus mock infection (one-way ANOVA on 
ranks, p<0.05). (F) Relative quantity of RSV N (left) and RSV G (right) expression via qRT-
PCR upon infection of Vero cells with SBA-labeled or unlabeled RSV A2 at an MOI of 1 at 
6, 12, and 24 hpi. There was no statistically significant difference at any time point (two-




SBA labels RSV G without inhibiting viral protein production 
Since SBA does not significantly impair the replication or infectivity of RSV A2 
when bound to virions prior to infection, we next sought to investigate if we could label 
RSV G on cells with SBA during an infection, without impairing viral processes. Because 
the majority of filaments are produced between 12 and 24 hpi, we incubated RSV infected 
cells with SBA-488 or vehicle control 12 hours hpi and allowed the cells to incubate a 
further 12 hours before fixation. Cells were then stained for RSV N and RSV F (Figure 
2.3A).  Labeling of RSV G with SBA-488 12 hpi was specific, and especially stained viral 
filaments in infected cells with minimal background (Figure 2.3B).  
We then verified that labeling of RSV G with SBA-488 12 hpi in live cells was not 
altering the amount of RSV G present in filamentous virions. To do this, we stained live, 
RSV infected cells with SBA-488 or vehicle control at 12 hpi, and harvested the virus at 
24 hpi. Then we isolated viral filaments and deposited them onto glass and immunostained 
for RSV F and RSV G (Figure 2.3C).  The amount of RSV G per filament was similar in 
SBA labeled and unlabeled RSV virions (Figure 2.3D). Finally, we verified that labeling 
RSV infected cells with SBA did not inhibit the release of progeny virions. We stained RSV 
infected cells with either SBA or vehicle control at 12 hpi, isolated the supernatant at 24 
hpi, and measured the titer by plaque assay (Figure 2.3E). There was no statistically 
significant difference between viral titers from SBA labeled and unlabeled RSV infected 
cells. Overall these results indicated that SBA can be utilized to specifically label RSV G 





Figure 2.3. SBA allows for the visualization of RSV G dynamics in RSV infected 
cells. (A) Vero cells were infected with RSV A2 at an MOI of 1.  At 12 hpi, cells were 
stained live with SBA-488 (top) or vehicle control (bottom), washed, and further incubated 
in complete growth media. 24 hpi, cells were fixed and immunostained for RSV N (blue), 
RSV F (red), and nuclei (gray). Scale bar represents 10 µm. (B) Enlarged cropped images 
from the white boxed regions from part (A) with intensity profiles showing colocalization 
along the direction of the white arrow. (C) Vero cells were infected with RSV A2 at an MOI 
of 1.  12 hpi, cells were stained live with SBA-488 (top, green) or vehicle control (bottom), 
washed, and further incubated in complete growth media. 24 hpi, virus was harvested. 
Filaments were isolated onto glass and stained for RSV F (blue) and RSV G (red) Scale 
bar represents 2 µm. (D) Mean sum of RSV G intensity per filament was quantified. 50 
isolated virions were analyzed for each condition. Error bars represent standard deviation. 
There was no statistically significant difference between SBA-labeled and unlabeled RSV 
(Mann-Whitney U test, p>0.05). (E) Vero cells were infected with RSV A2 at an MOI of 1.  
12 hpi, cells were stained live with SBA-488 or vehicle control, washed, and further 
incubated in complete growth media. 24 hpi, supernatants from single infected wells were 
titered by plaque assay in quadruplicate. Three wells were independently infected, 
stained, and assayed per treatment. Error bars represent standard deviation. There was 
no statistically significant difference between SBA-labeled and unlabeled RSV (Mann-




RSV G recycles from the plasma membrane 
To label the majority of the RSV G present during an RSV A2 infection, SBA-488 
was delivered in three doses at 12, 18, and 24 hpi to the same cells before fixation 24 hpi 
and immunostaining for RSV F. RSV G was found in viral filaments, as expected, as well 
as in intracellular vesicles, both of which colocalized with RSV F (Fig. 4a). We then 
performed a similar experiment and delivered an Alexa Fluor 647 conjugated SBA (SBA-
647) to infected cells 12 hpi first, and then, SBA-488 at 24 hpi prior to fixation and 
immunostaining for RSV F (Figure 2.4A). As expected, SBA labeled RSV G was found in 
viral filaments in both sets of cells, regardless of when it was delivered. RSV G labeled 
with SBA-647 delivered 12 hpi was found in intracellular vesicles rich in RSV F. 
Interestingly, RSV G labeled with SBA-488 delivered 24 hpi appeared in vesicles that do 
not colocalize with either RSV F or SBA-647 labeled RSV G. This finding suggested that 
RSV G is involved in a complex recycling mechanism where membrane-bound RSV G is 
first internalized and subsequently incorporated into viral filaments protruding from the 
surface. To confirm this, we delivered SBA-488 to live RSV A2 infected cells 12 hpi and 
immediately began imaging every 10 minutes (Figure 2.4B). Compared to the initial time-
point, we observed a dramatic reduction of SBA-488 staining on the surface of the cell, 
and a marked increase in the brightness and number of intracellular vesicles over a period 
of 1 hour. This demonstrated that RSV G is rapidly endocytosed into intracellular vesicles. 
Together, these data indicated that membrane bound RSV G recycles from the plasma 





Figure 2.4. RSV G recycles from the plasma membrane into intracellular vesicles. 
(A) Vero cells were infected with RSV A2 at an MOI of 1. Cells were either labeled with 
SBA-488 (green) at 12, 18, and 24 hpi (top) or with SBA-647 (red) at 12 hpi and SBA-488 
at 24 hpi. Cells were then fixed and stained for RSV F (blue). Enlargements of cropped 
images of either filaments or intracellular vesicles from the white boxed regions with 
intensity profiles showing colocalization along the direction of the white arrow. Scale bar 
represents 10 µm. (B) Vero cells were infected with RSV for 12 hpi before being labeled 
with SBA-488 (green). Immediately following SBA delivery, cells were imaged live over 1 






RSV G-containing vesicles may switch from clathrin to caveolin 
 
 We aimed to determine the mechanism by which RSV G recycles into the cell from 
the plasma membrane. We delivered SBA-488 to infected cells 12 hpi, fixed the cells 0, 
10, 30, and 60 min after delivery, and immunostained for clathrin heavy chain (CHC) 
(Figure 2.5A). We found that RSV G localized to the membrane immediately post-delivery, 
colocalized highly with CHC 10 minutes post-delivery and appeared to be released from 
clathrin coated vesicles 30 to 60 minutes after delivery (Figure 2.5B). Both the Pearson’s 
correlation and Mander’s coefficient for SBA-488/CHC confirmed these observations 
(Figure 2.5C). This indicated that RSV G is internalized from the membrane through the 
clathrin endocytic system. We confirmed these results using chlorpromazine, a potent 
clathrin-mediated endocytosis inhibitor. We incubated RSV infected cells 12 hpi with 
media containing chlorpromazine for 2 hours. We then labeled RSV G with SBA-488 and 
incubated the cells an additional hour before fixing and staining for CHC (Figure 2.5D). In 
chlorpromazine treated cells, RSV G was found in large intracellular granules that did not 
colocalize with CHC (Figure 2.5D). These results were confirmed with Mander’s 
colocalization analysis (Figure 2.5E). Finally, we labeled RSV G in infected cells 24 hpi 
before fixing and staining for caveolin and found high colocalization between RSV G and 
caveolin on viral filaments (Figure 2. 5F). Together, these data indicated that RSV G 
recycles into cells via clathrin-mediated endocytosis and over time, colocalizes with 





Figure 2.5. RSV G protein internalizes via clathrin and colocalizes with caveolin in 
viral filaments. (A) RSV infected Vero cells were stained for RSV G with SBA-488 
(green). The cells were incubated at 37 ºC before being fixed and stained for CHC at the 
indicated time points (red). The cell nuclei were stained with DAPI (blue). Scale bar 
represents 10 µm. (B) Enlargements of cropped images from the white boxed regions in 
part (A) with intensity profiles showing colocalization along the direction of the white arrow. 
(C) Mander’s colocalization coefficient and Pearson’s correlation between RSV G and 
CHC. Dotted line indicates 0 correlation. Error bars represent standard deviation. Asterisk 
indicates p<0.05 (Mann-Whitney U test). (D) Infected Vero cells at 12 hpi were treated 
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with the indicated concentration of chlorpromazine in media for 2 hours. RSV G was 
labeled with SBA-488 at 4 ºC followed by a 1 h incubation at 37 ºC in media with drug. 
Cells were fixed and stained for CHC. Scale bar represents 10 µm. Enlargements of 
cropped images from the white boxed regions with intensity profiles showing colocalization 
along the direction of the white arrow. (E) Mander’s colocalization coefficient between RSV 
G and CHC. Error bars represent standard deviation. Asterisk indicates p<0.05 (Mann-
Whitney U test) (F) Vero cells were infected with RSV A2 at on MOI of 1. At 24 hpi, RSV 
G was labeled with SBA-488 (green) and cells were fixed and stained for caveolin (red) 
and nuclei (blue). Enlargement of cropped image from the white boxed region with an 
intensity profile showing colocalization along the direction of the white arrow. Scale bar 




RSV filaments are formed via rapid vesicular distension 
Next, we examined the dynamics of filament formation in living cells. We infected 
cells with RSV A2 and labeled RSV G with SBA-488 16hpi. After 1 h, cells were imaged 
live at the maximum speed of our spinning disk confocal system (Figure 2.6A). 
Surprisingly, we found that some of the vesicles were distending and retracting into long 
filament-like structures. Additionally, we noticed that some of these structures appeared 
to branch, as has been observed previously for RSV filaments27. To determine the speed 
of these events, we measured their length across individual movie frames and found that 
both the lengthening and shortening of the structures occurred at a speed ≥ 2 µm/s (Figure 
2.6B). To ascertain whether these structures were viral filaments, we fixed the sample 
immediately after imaging and demonstrated colocalization for RSV F with SBA-488 
(Figure 2.7). To examine the motion of the filaments associated to vesicles, we infected 
cells with RSV A2 for 12 h before labeling RSV G with SBA-488. After 1 hour, cells were 
imaged live every 10 minutes for 12 hours (Figure 2.6C; Figure 2.8). As expected, we 
found that RSV filaments extended rapidly from vesicles within a single frame. 
Furthermore, some of these filaments persisted for a long period of time, suggesting that 
they had matured from the vesicular extension and retraction phase. These results 
indicated that RSV filaments are formed by a rapid extension/retraction process of 





Figure 2.6. RSV filaments are formed by a rapid vesicular extension and retraction 
motion. (A) Vero cells were infected with RSV A2 at an MOI of 1. At 16 hpi, SBA-488 was 
delivered and allowed to internalize for an hour. Cells were then imaged live at 12.13 Hz. 
Time series are shown with either even temporal spacing (top) or as selected frames from 
the movie (bottom). Yellow arrowheads indicate distension of vesicles, while arrows 
indicate extended filaments and branched filaments. Scale bar represents 5 µm. (B) 
Individual extension and retraction events were analyzed by hand on a frame-by-frame 
basis to determine the mean velocity. 30 events of each type were analyzed. Error bars 
represent standard deviation. (C) Vero cells were infected with RSV A2 at an MOI of 1. 
After 12 h, SBA-488 (green) was delivered to the cells and allowed to internalize for 1 h 
before being imaged every 10 minutes. Cropped regions of two individual filaments are 
shown. Yellow arrows mark the two apparent ends of the filaments. Scale bars represent 





Figure 2.7. Rapidly extending RSV G are RSV filaments. To confirm that the rapidly 
distending SBA-488 labeled structures were RSV filaments, the set of cells described in 
Fig. 6 for live-cell imaging was fixed and stained for RSV F (red) and nuclei (blue). Scale 





Figure 2.8. RSV filaments are of formed by extension of RSV G vesicles. (A) Vero 
cells infected for 12 hpi were stained with SBA-488 (green) and imaged live every 10 
minutes. Yellow arrows indicate progeny RSV filaments. Scale bar represents 10 µm. 
Cells are representative of duplicate experiments. (B) Cross-sectional views of the same 
cell 12 hpi and 20 hpi show RSV G granules moving from the intracellular compartment to 
the plasma membrane during the infection. The plasma membrane is represented by the 




Microtubules mediate intracellular filament formation 
 Because the speed of filament extension and retraction is similar to the previously 
reported speed of dynein-associated structures, we hypothesized that this motion was 
governed by molecular motors along microtubules92. To investigate this hypothesis, we 
examined the role of the cytoskeleton and molecular motors in the vesicular extension of 
RSV filaments. First, we used pharmacological agents to determine which cytoskeletal 
elements and which molecular motors are involved in the formation of the filaments. The 
effects of drug treatment were verified with immunofluorescence as previously 
described93. Cells were infected with RSV A2 and stained with SBA-488 12 hpi. After 1 h, 
cells were imaged live, before and after drug treatment. The motion of single vesicles was 
analyzed via single particle tracking by computing standard deviation (SD) maps for each 
image time series over 30 seconds. SD maps are generated by calculating the SD of the 
intensities on a per pixel basis over a given time frame, resulting in a 2D image of time 
series data. Fast moving particles result in large intensity fluctuations and correspondingly 
higher values on the SD map94,95. This resulted in fast moving objects appearing as 
streaks, while slow moving objects will appear as hollow circles, representing diffusive 
motion over time.  
While there was no change in the dynamics of filament extension when cells were 
exposed to the actin disruption agent cytochalasin D, all vesicular motion was halted when 
cells were exposed to the microtubule inhibitor nocodazole, to tetracaine, a promiscuous 
inhibitor of molecular motors, and to erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), a 
dynein-specific inhibitor (Figure 2.9A). Unexpectedly, filaments that were present prior to 
microtubule disruption were static and did not retract. This data suggested that 
microtubules were involved with the active extension and retraction motion, but not the 
structural stability of mature RSV filaments. To confirm these results, cells were 
transduced with GFP-tubulin, infected with RSV and stained with SBA-647 12 hpi. 
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Extending filaments were found to colocalize or be adjacent to microtubules, further 
supporting the observation that microtubules are involved with this motion (Figure 2.9B). 
Together, this data indicated that the microtubule motors are necessary for the formation 








Figure 2.9. Vesicular RSV filament formation is microtubule and dynein dependent. 
(A) Vero cells were infected with RSV A2 at an MOI of 1. At 12 hpi, SBA-488 was delivered 
to the cells and allowed to internalize for 1 h. Cells were then imaged live briefly at 9 Hz 
prior to drug delivery to verify the presence vesicular filament formation. Cells were then 
treated with nocodazole to disrupt microtubules, cytochalasin D to disrupt actin filaments, 
tetracaine to inhibit molecular motors, or EHNA to inhibit dynein before being imaged live 
again. Data is presented as SD maps over 30 s of imaging. Yellow arrows indicate fast 
motion, shown as streaks, while yellow arrowheads indicate slow motion, shown as hollow 
circles. Scale bars represent 5 µm. (B) Tubulin-GFP (green) was expressed in Vero cells 
overnight prior to infection with RSV A2 at an MOI of 1. At 12 hpi, SBA-647 (red) was 
delivered and allowed to internalize for 1 h. Cells were then imaged live at 4.9 Hz. Scale 




RNP granules merge with intracellular glycoprotein vesicles 
Currently, RSV F and RSV G, among other viral proteins, are thought to 
accumulate on the plasma membrane prior to genomic RNP trafficking, through an 
unknown mechanism, to the membrane where mature virions assemble 15,83,96. Because 
we observed that the formation of filaments takes place in the cytosol, as indicated by the 
involvement of microtubules and motors, we sought to investigate the spatial distribution 
of RSV M, RSV N, and RSV P relative to the connected vesicles and filaments observed 
in our live cell imaging experiments. Since these structures are lost upon permeabilization 
with 0.2% Triton X-100, we utilized 0.1% saponin to preserve them, as previously 
described21. RSV infected cells were stained with SBA-488 12 hpi and were allowed to 
incubate for 2 hours. Vero cells were then fixed in 1% paraformaldehyde, and 
immunostained for RSV F and either RSV M, RSV N, or RSV P (Figure 2.10A). In each 
case, RSV M, RSV N, or RSV P were found predominately in intracellular vesicles, while 
SBA-488 and RSV F were found both in the vesicles and the attached filaments. To 
confirm that these results were not limited to Vero cells, the experiment was repeated in 
HEp-2 cells with similar results (Figure 2.10B). These data indicate that RSV M, RSV N, 
and RSV P are present in vesicles alongside RSV F and RSV G prior to filament formation 





Figure 2.10. RNP granules merge with glycoprotein vesicles prior to the plasma 
membrane. (A) Vero cells were infected with RSV at an MOI of 1. 12 hpi, SBA-488 (green) 
was delivered and allowed to internalize for 2 h. Cells were then fixed with 1% PFA, 
permeabilized with 0.1% saponin, and stained for RSV F (blue) and either RSV P, RSV 
N, or RSV M, as indicated (red). Scale bar represents 10 µm in whole cell images and 1 
µm in cropped images. Enlargement of cropped image from the white boxed region with 
an intensity profile showing colocalization along the direction of the white arrow. (B) The 
same experiment in (A) was repeated in SBA-488 (green) stained HEp-2 cells. Cells were 
stained for RSV F (blue) and either RSV P, RSV N, or RSV M as indicated (red). Scale 
bar represents 10 µm in whole cell images and 1 µm in cropped images. Enlargement of 
cropped image from the white boxed region with an intensity profile showing colocalization 




Using RSV N as a marker for viral RNPs, we analyzed the colocalization of SBA-
488, RSV N, and RSV F in infected cells, where SBA was delivered immediately prior to 
fixation (Figure 2.11A). Since SBA was delivered before fixation and permeabilization, only 
RSV G on the plasma membrane was labeled. RSV F and RSV N were found to colocalize 
as early as 6 hpi and remained closely associated at every time point analyzed (Figure 
2.11B). This indicated that viral RNPs and RSV F interact very early during the course of 
infection within the cytosol, and not only at the membrane as reported previously24,83. This 
observation was confirmed using thresholded Mander’s colocalization analysis (Figure 
2.11C). The percentage of RSV N containing either RSV F or RSV G remained constant 
during the course of an infection due primarily to the large quantity of cytoplasmic RSV N. 
The colocalization between RSV N or RSV F and RSV G on the plasma membrane 
increased only at 24hpi, indicating that, at this stage, the cytoplasmic granules have 





Figure 2.11. RSV RNP granules merge with RSV G granules prior to the plasma 
membrane. (A) Vero cells were infected with RSV A2 at an MOI of 1. SBA-488 (green) 
was then delivered to the cells immediately prior to fixation at the indicated time-points 
post-infection. Cells were then stained for RSV F (blue), RSV N (red), and nuclei (gray). 
Scale bar represents 15 µm. (B) Enlarged cropped images from the white boxed regions 
from part (A) with intensity profiles showing colocalization along the direction of the white 
arrow. (C) Mander’s colocalization analysis was performed on 30 individual cells per time-





Viral genomic RNA is assembled with extended filaments 
 Because viral RNP granules appeared to colocalize with the cytoplasmic RSV G 
granules at early time points prior to viral filament formation, we hypothesized that viral 
genomes were assembled with progeny viral filaments after filament extension instead of 
concurrently. To test this, we used fluorescent, multiply labeled tetravalent RNA imaging 
probes (MTRIPs) to label and visualize the RSV genome11,97,98. Cells were infected with 
RSV A2 for 16 h prior to delivery of MTRIPs via streptolysin O (SLO). After membrane 
recovery from SLO exposure, SBA-488 was delivered to the cells and allowed to 
internalize for 1 h before live-cell two-color imaging.  Viral genomic RNA initially appeared 
only in bright SBA-labeled vesicles adjacent to SBA-labeled filaments (Figure 2.12A). 
Genomic RNAs were then rapidly localized, within 30 s, from the vesicle to the preexisting 
filament, as indicated by the increase of RNA signal along the filament and the 
corresponding decrease in the associated vesicle. This data supports our hypothesis that 
RSV genomes are localized to viral filaments after their extension. We then aimed to 
determine if microtubules were also involved with genomic RNA localization to RSV 
filaments. We repeated the above experiment upon treatment with nocodazole to disrupt 
the microtubule network and observed that the motion of all filaments and viral genomic 
RNAs was halted (Figure 2.12B). Together, these data suggest that RSV genomic RNAs 





Figure 2.12. RSV genomic RNA is assembled with extended filaments. (A) Vero cells 
were infected with RSV at an MOI of 1. At 12 hpi, Cy3B-labeled MTRIPs (red) targeted to 
RSV genomic RNA were delivered at 30 nM. After membrane recovery, SBA-488 (green) 
was delivered and allowed to internalize for 1 h. Cells were then imaged live at 4.3 Hz. 
Images were smoothed with a fine rolling ball filter in Volocity. Scale bar represents 1 µm. 
(B) Vero cells were infected with RSV at an MOI of 1. At 12 hpi, Cy3B-labeled MTRIPs 
(red) targeted to RSV genomic RNA were delivered at 30 nM. After membrane recovery, 
SBA-488 (green) was delivered and allowed to internalize for 1 h. Microtubules were then 







 To our knowledge, this study is the first instance of using fluorescently-conjugated 
lectins to image RSV glycoprotein dynamics in living cells. We demonstrated that SBA 
specifically binds RSV G in a manner that does not inhibit the infectivity or replication of 
the virus, and that SBA permits analysis of RSV G recycling and other dynamics in the 
context of viral infection.  
 The apical recycling endosome (ARE) is critical for RSV infections and specifically 
for the formation of filamentous virions, but the mechanism involved in the recycling of 
viral proteins is still unclear 8,10. Previous evidence indicated that RSV glycoproteins 
internalized in host cells via clathrin-mediated endocytosis and that this event is critical for 
productive RSV infection. However, these were only investigated in the context of viral 
entry 81,82. In this study, we labeled nascent RSV G after translation in the endoplasmic 
reticulum and transport to the plasma membrane through the Golgi complex. We found 
that RSV G recycled from the plasma membrane via clathrin-mediated endocytosis and 
that this mechanism might be associated with the production of RSV filaments, supporting 
the role of the secretory membrane system in filament formation. Future work will 
specifically address this issue. Additionally, these findings are substantiated by the 
recycling of glycoproteins of both Hendra virus and Nipah virus, two other members of the 
Paramyxoviridae family99,100. These results also corroborate previous studies on the role 
of clathrin-mediated endocytosis of both RSV G and the paramyxovirus parainfluenza 
virus type 5 (PIV-5) hemagglutinin-neuraminidase glycoprotein101,102. Additionally, our 
results indicate that RSV G eventually utilizes caveolin coated vesicles before 
incorporation into mature virions and filaments, both supporting and elaborating on 
previous studies on both RSV and PIV-583,26,103.  
 RSV filaments play a key role in the infectivity of the virus. Previous results, 
obtained analyzing fixed cells, were able to identify viral and host-cell proteins necessary 
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in RSV filament formation, but they were unable to investigate the dynamics of filament 
formation and genome localization as they were occurring 10,12,17,18,26–28. By utilizing SBA-
488 to directly label RSV G in living infected cells, we have recorded the first live images 
of wild-type RSV filament formation. While previous studies have observed filament 
formation over time, these results were obtained from imaging expressed GFP-fused host-
cell factors on the plasma membrane and not by labeling viral proteins26. We observed a 
rapid distension and retraction of vesicular RSV G into viral filaments following its recycling 
from the membrane. This mechanism is also responsible for the production of branched 
filaments, which have been observed in previous findings27. We measured that the speed 
of both filament extension and retraction is greater than 2 µm/s, similar to speeds reported 
for dynein-mediated vesicular transport92. These results support earlier reports that 
microtubules are involved with the assembly of progeny RSV and were confirmed using 
cytoskeleton disrupting drugs and molecular motor inhibitors23. Similarly, the assembly of 
filamentous Influenza A was found to be mediated by microtubules- and molecular motors-
dependent endocytic recycling of vesicles104–106. Finally, the role of microtubules in RSV 
filament assembly indicated that this extension process occurs in the cell cytoplasm prior 
to the plasma membrane, which supports and expands upon previous findings of RSV 
filaments budding into intracellular vesicles20,21.  
 Currently, the dynamics or molecular determinants of RSV genomic RNA 
localization and loading into progeny virions are unclear96. In the present study, we used 
fluorescence microscopy to analyze the colocalization of RNP and glycoprotein granules 
over the course of an infection and found that RNPs and glycoprotein vesicles merged as 
early as 6hpi. Additionally, by using a modified fixation and permeabilization protocol to 
improve the preservation of the structures seen in our live-cell imaging experiments, we 
found that these vesicles contained multiple RSV proteins, that are implicated in filament 
formation, while the filamentous extensions, at early time points, only contained RSV F 
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and RSV G17.  Because the ectodomain of RSV G appears to be cleaved in Vero cells 
during recycling, these results were confirmed in HEp-2 cells84. To concurrently track RSV 
filaments and genome in live infected cells, we utilized SBA-488 to label RSV G and 
fluorescent MTRIPs to target the RSV genome. We have captured the first recorded 
images, to our knowledge, of RSV genome loading in filaments, showing that this process 
occurs after the filament has formed, instead of simultaneously. We also demonstrated 
that this process is microtubule mediated, indicating that it occurs prior to plasma 
membrane, supporting and expanding on previous reports20,21.  
 Collectively, our results support a new model of RSV assembly and filament 
production (Figure 2.13). We utilized a fluorophore-conjugated SBA to selectively label 
nascent RSV G in live infected cells without interfering with RSV replication. Using this 
method, we determined that membrane bound RSV G recycles from the membrane 
through clathrin-mediated endocytosis. We also suggest that during the recycling process, 
RSV G vesicles undergo a transfer to caveolin coated vesicles, which is retained in mature 
filaments. Additionally, we report that RSV filaments and branched virions are formed prior 
to the plasma membrane through a microtubule and dynein dependent vesicular extension 
and retraction motion that occurs during the recycling process. Finally, we demonstrated 
that RSV glycoprotein and RNP vesicles merge prior to the plasma membrane and that 
RSV genomic RNA is loaded into extended filamentous virions in a microtubule mediated 
manner. While we only describe the use of fluorescent SBA specifically label RSV G, 
fluorescent lectins can be screened against the glycoproteins of other viruses, possibly 
allowing for the study of live glycoprotein dynamics in a variety of pathogens. Our data 
supports a new model in the assembly and loading of RSV filaments, inspiring questions 





Figure 2.13. Model of RSV filament formation prior to the plasma membrane via 
the rapid distension of vesicles along microtubules. Progeny RSV G is initially 
translated into the endoplasmic reticulum before being glycosylated and transported 
through the golgi network to the plasma membrane. RSV G, labeled with SBA, then is 
endocytosed and enters the recycling endosome compartment via clathrin-coated 
vesicles. These vesicles, which also contain RSV F, are distended by dynein along 
microtubules into filamentous particles prior to being loaded with RSV genomic RNA. 
During this recycling process, the vesicles colocalize with caveolin. The filaments then 







Viruses and Cell Lines 
Vero green monkey kidney cells (American Tissue Culture Collection CCL-81) or 
HEp-2 human epithelial cells (ATCC CCL-23) were cultured in DMEM (Lonza) 
supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 100 U mL-1 penicillin and 
100 mg mL-1 streptomycin (Life Technologies). Cells were plated on No. 1.5 coverslips 
(Electron Microscopy Sciences) or 35 mm glass-bottom dishes (In Vitro Scientific) one day 
prior to infection. Both Vero and HEp-2 cell lines were authenticated by ATCC and were 
checked for Mycoplasma contamination in our laboratory. HEp-2 cells are commonly used 
to propagate RSV in culture. 
Human RSV A2 (ATCC VR-1544) or rgRSV-GFP (a gift from Martin L. Moore’s 
lab, Emory University) was propagated in HEp-2 cells when the cells were >80% confluent. 
The media was removed and cells were washed with DPBS (without Ca2+ and Mg2+) from 
Lonza, and virus was added at a multiplicity of infection (MOI) of 0.1 for 1 h before adding 
complete medium to the inoculum. Cell-associated virus was harvested by scraping the 
cells when a high degree of cytopathic effects was visualized (about 90% or 96 hpi). Virus 
was then vortexed briefly, aliquoted, and stored at -80 ºC. Virus titers were measured via 
plaque assay. 
SBA labeling 
SBA conjugated to Alexa Fluor 488 and Alexa Fluor 647 was purchased from Life 
Technologies and reconstituted, stored, and used per the manufacturer’s protocol. Briefly, 
Vero cells were washed with DPBS without Ca2+ and Mg2+ before being incubated SBA 
diluted in HBSS (Lonza) to a final concentration of 20 μg/mL for 10 min unless otherwise 
specified. For RSV G colocalization and endocytic marker colocalization experiments, 
cells were chilled on ice for 10 minutes and SBA was delivered at 4 ºC to minimize 
endocytosis and nonspecific binding. Cells were then washed twice with fresh HBSS 
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before being either fixed, incubated further, or imaged. For live-cell imaging of 
microtubules alongside SBA, BacMam tubulin-GFP (Life Technologies) was delivered per 
manufacturer’s instructions 16 h before infection with RSV A2 at an MOI of 1.  
Synthetic mRNA production and transfections 
Plasmids for IVT were designed using the full length nucleotide sequences of RSV 
F and RSV G from RSV A2 (GenBank M74568.1). The coding region was followed by a 
3’ untranslated region (UTR) derived from the mouse alpha globin sequence. Sequences 
were codon optimized and inserted in a pMA-7 vector (Thermo Fisher Scientific, GeneArt) 
to be used as a template for mRNA synthesis. Plasmids were linearized with Not-I HF 
(New England Biolabs) overnight prior to IVT using a T7 mScript kit (Cellscript) following 
the manufacturer’s instructions. ATP, GTP, and CTP were used alongside m1Y-5’-
triphosphate (TriLink). RNAs were capped using 2’-O-Methytransferase followed by 
enzymatic addition of a poly-A tail, both according to the mScript kit instructions. The 
capped and tailed mRNAs were then purified using an RNeasy kit (Qiagen), treated with 
Antarctic Phosphatase for 2 hours (New England Biolaboratories), and purified again. 
Vero cells were transfected using a Neon electroporation system (Invitrogen) into a 24 
well plate were transfected with 1 µg of synthetic mRNA encoding RSV F or RSV G, 
respectively, according to the manufacturer’s protocol. Twenty hours post-transfection, 
cells were stained with SBA-488 at 4° C immediately before fixation and immunostaining 
without permeabilization. 
qRT-PCR 
 Vero cells were plated the day before infection in six-well plates. RSV A2 was 
incubated with 100 µg/mL of either SBA or vehicle control. Cells were then infected with 
the different virus treatments at an MOI of 1 for 24 h. Total RNA was extracted using an 
RNeasy kit (Qiagen) following the manufacturer’s protocol. mRNA was then isolated from 
total RNA using an Oligotex kit (Qiagen) following the manufacturer’s protocol. cDNA 
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synthesis was performed using the same amount of mRNA per condition and an RT2 First 
Strand kit (Qiagen) following the manufacturer’s protocol. qRT-PCR was then performed 
in triplicate using the RT2 SYBR Green ROX qPCR Mastermix (Qiagen) and primer sets 
(Table 2.1) described in Boukhvalvoa et. al.,107 on a Step-One Plus real-time thermocycler 
(Applied Biosystems). Rhesus Macaque GAPDH primers (Qiagen) were used as a loading 
control. Relative quantitation was performed using the Applied Biosystems software. 





Table 2.1. qRT-PCR primers used in Figure 2.2. 
Gene Forward Primer Reverse Primer 
RSV G CGGCAAACCACAAAGTCACA TTCTTGATCTGGCTTGTTGCA 
RSV N AAGGGATTTTTGCAGGATTGTTT CTCCCCACCGTAACATCACTTG 
 
 
MTRIP synthesis and delivery 
MTRIP design and synthesis is described in detail elsewhere97. Briefly, 2’-O-methyl 
RNA/DNA chimeric nucleic acid oligonucleotides targeting the RSV A2 genome contain a 
5’-biotin modification (Biosearch Technologies) and 5 internal dT amino groups. These 
ligands were then labeled with either Cy3B NHS ester (GE Healthcare) or DyLight 650 
NHS ester (Pierce) according to manufacturer instructions. Unbound dye was removed 
via centrifugation in a 3 kDa spin column (Millipore) and stored at -20 ºC until use. Probes 
were assembled by mixing labeled oligonucleotides with Neutravidin (Pierce) at a 5:1 
molar ration and allowed to react for 1 h at room temperature. Unbound oligonucleotides 
were filtered out by centrifugation through a 30 kDa spin column (Millipore). 
MTRIPs were delivered to cells at 30 nM concentration in Opti-MEM I medium 
(Invitrogen) containing 0.2 U mL-1 activated streptolysin O (Sigma) after washing the cells 
with DPBS without Ca2+ and Mg2+. The membrane was then allowed to recover in fresh 
growth medium for 15 min before imaging. 
Antibodies 
 For western blot, the primary antibody used was a mouse monoclonal anti-RSV G 
(Abcam, Cat. No. ab94966) diluted to 2 µg/mL in Odyssey blocking buffer (LI-COR) with 
0.1% Tween-20. The secondary antibodies were a donkey anti-mouse IRDye 680RD (LI-
COR) and a donkey anti-rabbit IRDye 800 (LI-COR) and were diluted 1:3000 in Odyssey 
blocking buffer with 0.1% Tween-20.  
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For immunostaining, primary antibodies used were mouse anti-RSV N (Abcam, 
Cat. No. ab22501), human anti-RSV F (MedImmune, palivizumab), mouse anti-RSV F 
(Abcam, Cat. No. ab94968), mouse anti-RSV G (a gift from Ralph Tripp, clone 130-6D), 
rabbit anti-caveolin-1 (Santa Cruz, Cat. No. sc-894), and mouse anti-clathrin light chain 
(Biolegend, Cat. No. MMS-423P). The mouse anti-RSV F antibody was used only for the 
mRNA expression experiments in Figure 1. All primary antibodies for immunostaining 
experiments were used at 1 µg/mL. Secondary antibodies used were donkey anti-rabbit 
Cy3 (Jackson ImmunoResearch), donkey anti-human Alexa Fluor 647, and donkey anti-
mouse Alexa Fluor 488 (Life Technologies). All secondary antibodies for immunostaining 
experiments were used at 4 µg/mL. 
Immunostaining 
Vero cells were fixed with 4% paraformaldehyde (PFA) (Electron Microscopy 
Sciences) for 10 min at room temperature before permeabilization with 0.2% Triton X-100 
(Sigma) for 5 min at room temperature. For experiments in Figure 8, cells were fixed in 
1% PFA for 10 minutes and permeabilized for 15 minutes in 0.1% saponin. Then, cells 
were blocked by incubation with 5% bovine serum albumin (Calbiochem) for 30 min at 
37ºC before being incubated with primary antibody for 30 min at 37 ºC. Cells were then 
washed with PBS and incubated with secondary antibody for 30 min at 37 ºC. Multiple 
antibody labeling was performed simultaneously after checking cross-reactivity. Cell 
nuclei were then stained with 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies), 
and coverslips were mounted onto glass slides with Prolong Gold (Life Technologies). 
Fixed and live-cell imaging 
Images for long-term infection experiments (Fig. 6b) were recorded with a 
Hamamatsu Flash 4.0 v2 sCMOS camera on a PerkinElmer UltraView VoX spinning disk 
confocal microscope mounted to a Nikon Ti-e body with a 60x, NA 1.49 CFI apochromat 
objective. All live-cell experiments were recorded using cells in 35mm glass-bottom dishes 
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with Leibovitz’s CO2 independent L-15 medium (Life Technologies) supplemented with 
10% FBS. Cells and dishes were kept at 37 ºC with a Pathology Device LiveCell stage top 
incubation system. Images were acquired with the Perfect Focus 3 system engaged to 
minimize temperature drift.  
All other images were acquired with a Hamamatsu Flash 4.0 v2 sCMOS camera 
on a PerkinElmer UltraView spinning disk confocal microscope mounted to a Zeiss 
Axiovert 200M body with a 63x NA 1.4 plan-apochromat objective. All images were 
acquired with Volocity (PerkinElmer) with Z-stacks taken in 0.2 µm increments. Cells and 
dishes were kept at 37 ºC during imaging by using a Chamlide TC-L live-cell stage-top 
environment with objective heater (Live Cell Instrument).  
Drugs 
After MTRIP delivery and SBA-labeling, Vero cells were incubated for 90 min with 
1 µM cytochalasin D (Sigma) for actin depolymerization, for 90 min with 4 µM nocodazole 
(Sigma) for microtubule depolymerization, or for 15 min with 1mM EHNA (Sigma) for 
dynein inhibition. After incubation, live-cell imaging was performed in Leibovitz’s L-15 
media. Tetracaine was used to promiscuously inhibit motors at 100 µM in L-15 and cells 
were imaged immediately. To inhibit clathrin-mediated endocytosis chlorpromazine 
(Sigma) was used at 10µg/mL and was delivered 2 hours prior to SBA delivery, and cells 
were incubated an additional hour in media containing the drug prior to fixation.  
Image processing 
All colocalization and object volume analysis was performed in Volocity. Movies 
were exported from Volocity as TIFF files and imported into ImageJ (NIH) for STD map 
generation using the ZProject plugin. To obtain intensity profiles, images were exported 
as TIFF files into ImageJ for analysis using the RGB profiler plugin, and results were 
plotted in Excel (Microsoft). Linear contrast enhancements were applied to images and 
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videos for clarity. All image quantification and analysis was completed on unenhanced 
data.  
Western blotting 
Vero cells were plated the day before infection in six-well plates. RSV A2 was 
incubated with 100 µg/mL of either SBA or vehicle control. Cells were then infected with 
the different virus treatments at an MOI of 1 for 24 h. Cells were lysed with RIPA buffer 
(Pierce) containing 1x Complete Protease Inhibitor (Rosche) before being scraped and 
clarified by centrifugation. Protein concentration was calculated using a BCA assay 
(Pierce) following the manufacturer’s protocol. Lysates were stored at -80 ºC until further 
use.  
For gel electrophoresis, 12 µg of lysates were mixed with 4x SDS loading buffer 
(LI-COR Biosciences), boiled for 10 min at 70 ºC, chilled on ice, and loaded into wells of 
a Novex 10% Bis-Tris precast gel (Life Technologies) alongside a molecular weight 
marker (LI-COR). Gel was run in an XCell Surlock Mini Cell system (Life Technologies) in 
1X MOPS running buffer (Life Technologies) at a constant 200V for 50 min. Protein was 
then transferred to 0.45 µm pore nitrocellulose membranes (Life Technologies) in 1x 
Western transfer buffer (Life Technologies) at a constant 30 V for 1 h using an XCell II 
Blot module (Life Technologies). 
Western blots were stained using a Snap i.d. blot holder (Millipore). Nonspecific 
binding was blocked using Odyssey blocking solution at room temperature (LI-COR). 
Vacuum was then immediately applied for 20 s to remove solution. Primary antibody, 
including a rabbit anti-ß-actin antibody (Cell Signaling Technology, Cat. No. 8457) loading 
control (diluted 1:1000), was then applied and allowed to incubate for 10 min. Vacuum 
was then applied and the blots were washed three times with 1x PBS containing 0.1% 
Tween-20 (PBST). Secondary antibody was then applied and allowed to incubate for 10 
min before blots were again washed three times with PBST. Blots were imaged using an 
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Odyssey IR scanner (LI-COR). Only linear contrast enhancements were performed for the 
final representative images.  
Virus neutralization assay 
rgRSV-GFP stocks were mixed with the indicated concentrations of SBA, 
palivizumab, or vehicle control and allowed to bind for 2 h on a tube rotator at 37 ºC. Vero 
cells were then infected at an MOI of 1 with the virus treatments or control containing only 
complete growth medium. 3 hpi, cells were washed with with a 40 mM sodium citrate 
solution containing 10 mM potassium chloride and 135 mM sodium chloride (Sigma) 
adjusted to pH 3.0 to eliminate any virus that had not yet internalized before being returned 
to complete growth medium. 48 hpi, cells were lifted into single-cell suspensions with 
0.25% Trypsin (VWR) before being suspended in FACS buffer (DPBS without Ca2+ and 
Mg2+, supplemented with 1% FBS and 5mM EDTA). Cells were then analyzed for GFP 
fluorescence with an Accuri C6 flow cytometer (BD Biosciences).  
Viral filament isolation 
SBA-488 (20µg/mL) was mixed with RSV-A2 stocks for 30 minutes at 37 ºC before 
filtration and isolation of viral filament as described previously11. Briefly, SBA-labeled virus 
was first centrifuged through 5 and 0.45 µm filters (Millipore) at 5,000 g and 4 ºC for 4 and 
1 min, respectively, to remove the dead cell debris from the cell-associated RSV stock. 
For imaging RSV virion on glass, coverslips were coated with poly-L-lysine (Sigma) in a 
24-well plate. Labeled and filtered virion were then centrifuged onto the surface of the 
coverslips for 30 min at 4ºC and 2,400 g. For infecting cells with SBA-labeled virus, titer 
was adjusted accordingly to an MOI of 1 before inoculating Vero cells.  
Statistical analysis 
 Results were plotted and statistical analyses were performed using Prism 7 
(GraphPad). Power analysis was performed to ensure adequate sample size for 
experiments. For two-group comparisons, the Mann-Whitney U test was performed. For 
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comparisons of greater than two groups, one-way ANOVA on ranks or two-way ANOVA 
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Background 
 
 Acute respiratory infections are responsible for the hospitalization and deaths of 
millions of individuals annually worldwide1. Current vaccine strategies are limited to 
inactivated, recombinant, and live-attenuated types, though nucleic acid vaccination is 
actively being investigated in preclinical and clinical trials108–114. These approaches, 
though very powerful, take time to take effect, limiting their utility during pandemics.  
Additionally, prophylaxis remains limited to antivirals and, in the case of respiratory 
syncytial virus (RSV), the broadly neutralizing antibody palivizumab is the only FDA 
approved treatment for high-risk populations. The limited application of palivizumab is 
likely due to its debated efficacy. Palivizumab, delivered by intramuscular (IM) injection, is 
present in the serum at titers 2,000 fold higher than in bronchoaveolar lavage (BAL) 
samples5. This indicates that the majority of palivizumab injected IM is not delivered to the 
appropriate organ compartment to neutralize the virus, which potentially explains the 
limited reduction in hospitalization rates observed in treated infants3. Therefore, there is a 
need for a rapidly-expressed, targeted prophylaxis technique to prevent pulmonary 
infections. 
 To date, no DNA-based therapeutics have been approved for human use due 
primarily to safety concerns. First, DNA-based therapeutics incite concerns of integration 
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into the host genome, and while this effect has been found to be minimal to date, 
integration must continue being monitored for each antigen expressed by the DNA39,40. 
Modified adeno-associated viruses (AAV) are a prominent vehicle for nucleic acid 
therapeutic delivery, in part due to being replication deficient and minimally pathogenic52–
54. However, because AAV-based therapies are permanent and elicit an immune 
response, repeated dosing is not currently possible56–58. Moreover, this immune response 
would preclude the ability to deliver additional AAV-based therapeutics targeting different 
pathogens or additional strains. 
Delivery of therapeutic-encoding mRNA, directly to the lung, aims to safely and transiently 
increase therapeutic protein concentration in the target organ, compared to systemic 
purified recombinant protein delivery, frequently administered IM70,115,116. Additionally, 
more protein is produced during peak expression following delivery of naked mRNA 
compared to naked plasmid DNA51. Still under investigation, aerosol delivery of mRNA 
has been shown to elicit transient protein expression that is capable of treating disease70–
72. Targeted delivery of therapeutics to the organ of interest has the potential to minimize 
systemic toxicity, anti-antibody immune responses, and reduce the amount of drug 
required to achieve therapeutic levels.  
 Here, we developed a modular toolbox to express synthetic, modified mRNA and 
prevent viral infections in the lung. First, we expressed whole palivizumab (secreted, 
termed sPali) in the lung via synthetic mRNA delivery by intratracheal aerosol. Second, 
we linked the well characterized glycosylphosphatidylinositol (GPI) membrane anchor 
sequence from the decay accelerating factor (DAF) to the palivizumab heavy chain mRNA 
(Figure 3.1A-B)117,118. Anchored palivizumab was termed aPali; we expected that cells 
transfected with aPali would retain the immunoglobulin on the epithelial surface, 
increasing its concentration in the lung and improving efficacy. Finally, we demonstrated 
that the GPI anchor is adaptable to other constructs by linking it to a RSV-neutralizing 
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VHH camelid antibody (aVHH), previously demonstrated to be more potent than 
palivuzmab119. The anchored VHH also inhibited RSV infection in vitro and in vivo.  
In this study, we found that mRNA-expressed anchored neutralizing antibodies, both 
whole and single domain: (1) are rapidly expressed and retained on the surface of 
transfected cells in culture and in mouse lungs, (2) prevented RSV infection in vitro and in 
vivo, and (3) were minimally immunogenic. Together, these technologies comprise a 
modular mRNA toolbox to express a variety of engineered neutralizing antibodies to 
prevent pulmonary infections. 
aPali is anchored to the plasma membrane and prevents RSV infection in 
transfected cells 
 
We first verified the assembly of whole antibodies expressed from synthetic mRNA 
by staining with an anti-human IgG antibody in vitro. The anti-human IgG antibody 
efficiently stained cells co-transfected with mRNAs encoding for the light and heavy chains 
at a 1 to 4 molar ratio. No staining was observed in cells transfected with only light chain 
mRNA, while cells transfected with only the heavy chain mRNA showed significantly lower 
staining. Therefore, we concluded that the mRNAs for both heavy and light chains were 
efficiently translated to form whole IgG antibody (aPali) (Figure 3.1C).  
Next, to establish that the GPI membrane anchor encoded in the heavy chain 
sequence was functional, we transfected cells with mRNA encoding for either aPali or 
sPali, and compared the localization of assembled antibodies at 2, 4, 6, 12, and 24 hours 
post transfection, with and without Triton-X permeabilization (Figure 3.1D).  Without 
permeabilization, strong surface staining was visible as early as 2 hours in cells 
transfected with aPali mRNA, indicating rapid antibody production and localization to the 
plasma membrane. The surface staining was strongest between 6 and 12 hours after 
transfection and remained so at 24 hours after mRNA delivery. In contrast, in cells 
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expressing sPali mRNA, membrane staining was minimal, indicating that the expressed 
antibodies were not localized to or concentrated on the plasma membrane.  
When the localization was evaluated with permeabilization, sPali was found in the 
secretory membrane system from 2 to 12 hours after transfection, with a dip in intensity at 
24 hours, possibly due to both the decreased mRNA expression and diffusion of sPali into 
the growth media. Interestingly, aPali can be observed in the secretory membrane 
pathway from 2 to 6 hours after transfection, but at lower concentrations, indicating a 
reduced accumulation in this cell compartment as well as on the plasma membrane as 
early as 2 hours post-delivery. Together, these data show that the GPI encoded 
membrane anchor is functional, and anchoring the antibody on the membrane prevents 
aPali diffusion into the growth media. 
To demonstrate that aPali can bind and inhibit RSV infection, we transfected cells 
with mRNA encoding either the heavy chain, the light chain, or both the heavy and light 
chains. The cells were infected with RSV 24 hours after mRNA delivery; infected cells, not 
exposed to the mRNA, were used as a positive control. Cells were then fixed, 
permeabilized, and stained for aPali, RSV nucleoprotein (RSV N), and with a panRSV 
polyclonal antibody (Figure 3.1E).  No infection was detected in cells transfected with both 
the heavy and light chain of aPali. This demonstrates that transfection with both chains is 
required for successful binding and neutralization of RSV. This was quantified by 
measuring the volume of RSV N signal upon infection (Figure 3.1F). In untransfected cells, 
RSV replicated, with the RSV N signal representing approximately 21% of the total volume 
per cell. In aPali transfected cells, we detected a 99% reduction in the volume of RSV N, 
with the residual signal likely derived from the viral particles in the inoculum.  In addition, 
aPali mRNA transfection resulted in a 2 log reduction of infectious RSV titer via plaque 
assay (Figure 3.1G, Figure 3.2). Overall, these data demonstrate that aPali mRNA 




Figure 3.1. aPali is anchored to the plasma membrane and prevents RSV infection 
in transfected cells. (A) Schematic of aPali anchored to the plasma membrane. (B) 
Schematic of aPali and sPali mRNA delivery and expression. (C) Cells were transfected 
with vehicle control or 1 μg of either aPali heavy chain only, aPali light chain, or both the 
heavy and light chain mRNAs. 24 h later, cells were fixed, permeabilized, and stained with 
a donkey anti-human secondary antibody (white). Scale bar represents 10 μm. (D) Cells 
were transfected with 1 μg of either aPali or sPali mRNA. At 2, 4, 6, 12, and 24 hours, 
cells were fixed, permeabilized or not, and stained for the expressed antibody (white). 
Scale bar represents 10 μm. (E) Cells were transfected with vehicle control or 1 μg of 
either aPali heavy chain only, aPali light chain only, or both the heavy and light chain 
mRNAs. After overnight incubation, cells were infected for 24 h before being fixed and 
stained for RSV N (green), panRSV (blue), and aPali (red). Scale bar represents 10 μm. 
(F) Quantification of the mean volume of the RSV N signal per cell from microscopy 
images in part (E). Error bars represent 95% confidence intervals. Asterisks indicate 
p<0.0001 (Mann-Whitney U test). (G) Cells were transfected with vehicle control or 1 μg 
of aPali and infected with RSV at MOI of 0.01, 0.1, and 1. Supernatants were collected at 
24 hpi and virion titers were measured by plaque assay. Boxes represent 25th and 75th 
percentile along with the mean, while whiskers represent the minimum and maximum 
values. Dotted line represents lower limit of detection. Asterisks indicate p<0.0001 (one-




Figure 3.2 – aPali reduces RSV titer on transfected cells. Cells were transfected with 
1 μg of aPali or left untransfected. After 24 h, cells were infected with 50 PFU of RSV A2. 
Virion titer was determined by plaque assay directly on the transfected or control cells. 




Mechanism of action of aPali prophylaxis evaluated by super-resolution 
microscopy 
 
 Next, we sought to delineate the mechanism by which aPali prevented infection of 
transfected cells. Conventional spinning disk confocal microscopy does not afford the 
necessary axial resolution to determine if RSV particles are internalized in aPali 
transfected cells or merely attached to the plasma membrane (Figure 3.3A). To overcome 
the resolution constraint, we employed a 3D direct stochastic optical reconstruction 
microscopy (dSTORM) system with ~20 nm lateral and ~50 nm axial resolution. We 
transfected cells with aPali mRNA overnight before infecting them with RSV. At 2 and 20 
hpi, cells were fixed and immunostained for aPali and RSV N, with and without 
permeabilization. In untransfected cells infected with RSV, large inclusion bodies and long 
filaments were visible (Figure 3.4). In transfected cells, using dSTORM, we observed aPali 
at the plasma membrane along the contour of the cell (Figure 3.3B). Additionally, at 2 and 
20 hpi, individual RSV virions were observed at the aPali-labeled membrane. Specifically, 
at both time points, single virions of ~100-300nm, the expected size of spherical-like RSV 
particles, were localized 180 nm (at 2 hpi) and 113 nm (at 20 hpi) above the plasma 
59 
 
membrane (Figure 3.3C). These results revealed that RSV particles were not internalized 
over time, demonstrating that the mechanism by which aPali inhibits infection is by 





Figure 3.3. Mechanism of action of aPali prophylaxis evaluated by super-resolution 
microscopy. (A) Vero cells were transfected with 1 μg of aPali and infected with RSV at 
MOI of 1. At 24 hpi, cells were fixed, stained with anti-human secondary (green) and for 
RSV N (magenta) and imaged using a confocal microscope. Cropped image is a 
magnification of white box inset. Cross section is along the white line in the cropped image. 
Scale bar in whole cell represents 10 μm, while scale bar in cropped image represents 5 
μm. (B) The same cells from part (A) were imaged using 3D dSTORM. Cells were fixed 
at either 2 or 20 hpi and permeabilized or not, as indicated. Widefield reference images 
were captured on the same microscope immediately prior to acquisition, with the cropped 
region indicating magnification of the white box. dSTORM images were acquired on the 
widefield cropped region. Cross section views are shown from a 2 μm slice through the 
XY image as indicated by the white lines. Arrowheads indicate single RSV virions. Scale 
bar in the widefield images represent 20 μm, while scale bars in the widefield crop and 
dSTORM images represent 5 μm. Scale bar “L” represents 2 μm in both directions. (C) 
Single RSV particles were cropped from white boxes in the dSTORM images from 
unpermeabilized cells in part (B). XY views as well as XZ and YZ are shown. Scale bars 
represent 700 nm. Individual viral particles were isolated in software and the mean 
distance in the z direction between the aPali and RSV N signals per particle was 
determined at 2 and 20 hpi. Error bars represent 95% percent confidence interval. No 




Figure 3.4. dSTORM imaging of untransfected cells infected with RSV. (A) 
Untransfected Vero cells were infected with RSV at MOI of 1. At 24 hpi, cells were fixed, 
stained with for RSV F (top) and RSV N (bottom) and imaged using the widefield function 
on the Vutara. (B) The same region from partA was analyzed using dSTORM, with RSV 
F pseudocolored green and RSV N pseudocolored magenta. Cropped inclusion body is 
indicated by the white box in the whole frame view. The section of the inclusion body is 
indicated by the white rectangle in the cropped image. XY (top) and YZ (bottom) cross-
sections are shown.   
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Lung distribution of aPali mRNAs and mRNA expression in the lung epithelium 
 
Before performing in vivo challenge studies, we first aimed to determine the 
distribution of aPali mRNA in the lung. To accomplish this, we used fluorescent multiply 
labeled RNA imaging probes (MTRIPs) bound to the mRNA prior to delivery93,97. Recently, 
we demonstrated that this method allowed for the tracking of exogenous mRNA using a 
variety of detection techniques while not significantly impacting translation120. We labeled 
aPali heavy chain mRNA with Dylight-650 MTRIPs and aPali light chain mRNA with Cy3B 
MTRIPs and delivered the labeled mRNA into the lungs of BALB/c mice by intratracheal 
aerosol. Animals were sacrificed after 4 hours and heavy and light chain mRNA 
distributions in the lung were analyzed by confocal microscopy. In the transfected lungs, 
mRNA was distributed throughout the tissue (Figure 3.5A). High magnification images 
confirmed that both the heavy and light chain mRNAs colocalized in discrete granules 
inside transfected cells (Figure 3.6A). We then analyzed the colocalization of the 
exogenous mRNA with either Rab5, an early endosome marker, or Rab7, a late endosome 
marker. We found that 24.4% of the delivered mRNA colocalized with late endosomes and 
39.7% with early endosomes, indicating that some of the mRNA was still trafficking 
through the endosomal system of alveolar cells at 4 hours post transfection (Figure 3.6B, 
Figure 3.5B). Notably, since only half of the mRNA was associated with endosomal 





Figure 3.5. Labeled aPali biodistribution in lung lobe. (A) Cy3B labeled light chain 
(red) and DyLight 650 labeled heavy chain (green) mRNA was transfected into the lungs 
of mice (left). Saline was injected as a negative control (right). At 4 hours, lungs were 
excised and cryosectioned before being imaged. Scale bar represents 750 μm. (B) Control 
tissue sections from part (A) were stained for Rab5 or Rab7 (green) for early or late 




Next, we assessed whether aPali mRNA was expressed and retained on the 
surface of transfected cells in vivo.  We delivered aPali or sPali encoding mRNA using 
Viromer RED (VR), a modified form of PEI, to the lungs of BALB/c mice using intratracheal 
aerosol. After 4 hours lung tissue sections were stained for the expressed antibody and 
imaged (Figure 3.6D). Lungs transfected with aPali displayed a strong antibody signal on 
the apical surface of the airway epithelial cells. On the contrary, lungs transfected with 
sPali showed pockets of expressed antibody predominately within alveolar epithelial cells. 
Then, we evaluated the distribution of DyLight-680 labeled mAb palivizumab injected via 
IM, and studied the distribution of the antibody in vivo using a handheld near-infrared 
imager as well as with microscopy. We found that the DyLight 680-labeled antibody was 
present in the lung, as well as throughout the body, with the most intense fluorescent 
signal in the injected tibialis muscle (Figure 3.7). Next, we sought to quantify the 
percentage of lung cells expressing aPali upon intratracheal aerosol. We transfected mice 
with mRNA encoding the aPali heavy chain and a light chain sequence modified with a C 
terminus V5 peptide tag, included to improve detection via flow cytometry. After 24 hours, 
mice were sacrificed and the lungs were analyzed for V5 expression by flow cytometry. 
We found that in two of the transfected mice, more than 70% of the isolated lung cells 
were expressing aPali-V5 (Figure 3.6E). This indicated that aPali can be expressed in 





Figure 3.6. Lung distribution of aPali mRNAs and mRNA expression in the lung 
epithelium. (A) Cy3B labeled light chain (red) and Dylight 650 labeled heavy chain 
(green) mRNA was transfected into the lungs of mice. At 4 hours, lungs were sectioned 
and imaged on a whole tissue (top) or single cell basis (bottom). Scale bar represents 
either 200 μm (top) or 5 μm (bottom). (B) Tissue sections from part (A) were stained for 
Rab5 or Rab7 (green) for early or late endosomes, respectively. Scale bar represents 5 
μm. Cropped regions are magnifications of white boxes in whole cell images with intensity 
profiles along the direction of the white arrow. (C) Mander’s colocalization coefficient and 
Pearson’s correlation between light chain mRNA and Rab5 or Rab7. Dotted line indicates 
0 correlation. n ≥ 10 cells per group. Error bars represent 95% confidence interval. Asterisk 
indicates p < 0.05 by two-tailed t-test. (D) Mice lungs were transfected with either sPali 
(top) or aPali (bottom) mRNA using Viromer Red. At 4 hours, tissue sections were stained 
for the expressed antibody (white). Scale bar represents 25 μm. (E) Mice lungs were 
transfected with aPali heavy chain and V5 tagged light chain mRNA. Flow cytometry was 
performed on dissociated lungs stained for V5. Histograms of V5 intensity were 





Figure 3.7. NearIR labeled palivizumab biodistribution. (A) DyLight 680 labeled 
palivizumab was delivered into the tibialis of mice. Saline was injected as a negative 
control. After 24 h, mice were sacrificed and dissected. Mice were imaged using the 
Fluobeam Near-IR imager. In both animals, the gut is fluorescent due to the diet. (B) 
Specific organs from injected animals, including the lungs (left), injected tibialis muscle, 
spleen (middle), and liver (right) were excised and imaged. Images were taken with the 
ambient light off (top) and on (bottom) to provide context for the control animals. (C) Three 
other mice were processed and imaged as in part (B). (D) DyLight 680 labeled palivizumab 
(green) was delivered into the tibialis of mice (left). Saline was injected as a negative 
control (right). At 24 hours, lungs were excised and cryosectioned before being imaged. 
Scale bar represents 750 μm.   
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Optimizing mRNA delivery vehicle and dosage 
 
To optimize the delivery of therapeutic mRNA to the lung, we compared several 
mRNA formulations and doses. We first aimed to find the optimal delivery vehicle for 
aerosol-mediated transfection into the lungs, which would yield effective inhibition of RSV 
infection. We evaluated several commercially available vehicles including VR and in vivo-
jetPEI, both PEI derivatives, as well as naked mRNA delivery in water. We transfected 
mice intratracheally with 40 μg of aPali mRNA, and after 24h, they were infected with RSV 
L19 intranasally. All three delivery vehicles significantly reduced RSV F copy numbers 
compared to the saline positive control (Figure 3.8A). Specifically, naked mRNA and 
mRNA delivered by VR reduced RSV F mRNA copy number by 91 and 96%, respectively. 
Additionally, only naked and VR delivered mRNA significantly reduced RSV viral titers in 
lung homogenate supernatants, by 75.4% and 74.2% respectively (Figure 3.8B). To 
determine the immunological effects of the delivery vehicles and mRNA, we measured the 
mRNA levels of interleukin 6 (IL-6), RANTES, and interferon gamma (IFNg) and beta 
(IFNb) and found that in vivo-jetPEI increased IFNb mRNA levels by 257-fold, 
commensurate with a significant decrease in body weight on days 1 and 2 post 
transfection (Figure 3.8C, Figure 3.9). The increase in IFNb mRNA levels indicated an 
increase in immune activation, which was not observed using VR or naked mRNA delivery. 
Finally, to investigate the extent of RSV infection, we also cryosectioned and 
immunostained lungs from each group using a pan-RSV polyclonal antibody. While both 
the saline positive control and in vivo-jetPEI groups yielded multiple pockets of infection 
throughout the lung, minimal RSV staining was observed when aPali mRNA was delivered 
either by VR or naked, with the latter having the more dramatic impact (Figure 3.8D). To 
minimize immunological risk, maximize prevention of RSV infection, and increase 
translational suitability, naked mRNA delivery was used for subsequent experiments. 
68 
 
 Next, we optimized the mRNA dose by delivering 20 or 100 μg of aerosolized aPali 
mRNA, intratracheally. To compare the therapeutic effect of aPali mRNA to injected 
palivizumab, we also administered 15 mg/kg (300 μg for a 20 g mouse in 25 μl of saline) 
of antibody by IM injection into the tibialis muscle. At 4 dpi, mice were sacrificed and lungs 
were excised, processed for mRNA extraction, and total RSV F mRNA copy number was 
measured by qRT-PCR. We found that 100 μg of aPali mRNA significantly reduced RSV 
F copy number by 90% (Figure 3.8E). Remarkably, delivering 100 μg of aPali mRNA was 





Figure 3.8. Optimizing mRNA delivery vehicle and dosage. (A) Mice lungs were 
transfected with 40 μg of aPali mRNA using the indicated delivery vehicles. Saline and 
negative controls are indicated. 24 hours later, mice were infected with RSV L19. At 4 
days post infection, mice were sacrificed and lungs were excised and processed for mRNA 
extraction. Mean RSV F copy number was determined by qRT-PCR. Error bars represent 
standard deviation. Asterisk indicates p<0.05 (one-way ANOVA, Tukey’s multiple 
comparisons). (B) The same mouse lungs from part (A) were processed and RSV virions 
were measured by plaque assay. Error bars represent standard deviation. Asterisk 
indicates p<0.05 (one-way ANOVA, Tukey’s multiple comparisons). (C) Mice lungs from 
part (A) were analyzed by qRT-PCR for the relative quantity of mRNA for IL-6, CCL5, 
IFNg, and IFNb. Error bars represent standard deviation. Asterisk represents p<0.05 
(Kruskal-Wallis, Dunn’s multiple comparisons). (D) Mice lungs were transfected as in part 
(A). Lungs were processed for cryosectioning and stained with panRSV antibody (green). 
Scale bar represents 100 μm.  (E) Mice lungs were transfected with 0, 20, or 100 μg of 
aPali mRNA using the indicated delivery vehicles. Palivizumab injection IM was included 
as a positive control. 24 hours later, mice were infected with RSV L19. At 4 dpi, mice were 
sacrificed and lungs were excised and processed for mRNA extraction. Mean RSV F copy 
number was determined by qRT-PCR. Error bars represent standard deviation. Asterisk 
indicates p<0.05 (one-way ANOVA, Tukey’s multiple comparisons). # indicates no 





Figure 3.9. Use of in vivo-jetPEI results in rapid weight loss in transfected mice. 
Mice from the experiment in Fig. 4a were weighed each day after transfection. Weights 
were normalized by the mean of day 0 in each group. Y-axis begin at 0.7 to better show 
the differences in weight between the treatment groups. Error bars represent 95% 




mRNA-expressed palivizumab prevents RSV infection in vivo with minimal 
cytokine response 
 
 We then compared the RSV-neutralizing ability of aerosolized aPali mRNA and 
sPali mRNA (100 μg) to IM palivizumab (300 μg) and saline controls, given 
prophylactically. Twenty four hours post-delivery, mice were infected with RSV L19. Mice 
were sacrificed and lungs excised at 4 dpi and processed for cryosectioning, protein and 
virus collection, and RNA extraction. We found that aPali and sPali mRNA significantly 
reduced viral titers by 65% and 89%, respectively (Figure 3.10A), when supernatants were 
analyzed for virion production. As expected, palivizumab IM yielded no detectable 
plaques, due to free antibody neutralization of RSV virions directly in the supernatant.  All 
treatments significantly limited RSV replication in the lung (Figure 3.10B), reducing RSV 
F copy number by approximately 90%. Next, the RSV infections and treatments were 
evaluated microscopically.  We found that while bright pockets of RSV infection throughout 
the tissue were visible in the saline control group, aPali and sPali mRNA delivery 
significantly reduced the RSV staining (Figure 3.10C, Figure 3.11); specifically, aPali 
reduced the volume of RSV signal by more than 70% (Figure 3.10D-E). The safety of 
mRNA delivery to the lung was also assessed by measuring cytokine protein 
concentrations 5 days post transfection using a multiplexed immunoassay. None of the 
measured cytokines, RANTES, IL-12 p70, MIP-1a, and IL-6, were statistically different 
from mock transfected cells (Figure 3.12).  Overall, we have demonstrated that mRNA-
expressed neutralizing antibodies in the lung are an effective method of preventing RSV 





Figure 3.10. mRNA-expressed palivizumab prevents RSV infection in vivo with 
minimal cytokine response. Mice lungs were transfected with 100 μg of naked aPali 
mRNA. Saline and negative controls are indicated. 24 hours later, mice were infected with 
RSV L19. At 4 days post infection, mice were sacrificed and lungs were excised. A total 
of 10 mice were used per group, out of which, 8 were processed for mRNA, protein, and 
virion extraction, with 2 being prepared for cryosectioning. (A) Virion content of mice lung 
homogenate supernatants was assayed by plaque assay. Error bars represent standard 
deviation. Asterisk indicates p<0.01 (one-way ANOVA, Tukey’s multiple comparisons). (B) 
Mean RSV F copy number was determined by qRT-PCR. Error bars represent standard 
deviation. Asterisk indicates p<0.01 (one-way ANOVA, Tukey’s multiple comparisons). (C) 
Cryosections were stained with panRSV antibody (green). Scale bar represents 100μm. 
(D) Quantification of mean volume of RSV signal per frame from microscopy images in 
part (C). Error bars represent 95% confidence intervals. Asterisks indicate p<0.01 
(Kruskal-Wallis, Dunn’s multiple comparisons). (E) For thresholded comparison, images 
with less than 400 μm3 signal were excluded. Error bars represent 95% confidence 




Figure 3.11. Extent of RSV infection in transfected mice. (A) Additional tissue sections 
were imaged from the experiment in Fig. 5d. Staining for panRSV is in green. Scale bar 
represents 100 μm. (B) Mice were injected IM into the tibialis muscle with 300 μg of 
palivizumab and infected with RSV L19 the next day. At 4 dpi, animals were sacrificed and 
lungs were excised, cryosectioned and stained with panRSV (green). Scale bar represents 





Figure 3.12. Cytokine protein levels in transfected and infected mice. Lung 
homogenates were analyzed by bead-based immunoassay for cytokine protein levels of 
RANTES, IL12 p70, MIP-1α, and IL-6. Error bars represent 95% confidence intervals. 
Undetermined values were set to 0.1 pg/mL. No group was found to be significantly 
different from another (Kruskal Wallis).  
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Adapting the GPI anchor to single-chain antibodies 
 
To demonstrate that the GPI anchor is adaptable to other classes of neutralizing 
antibodies, we designed and produced an mRNA encoding for a newly discovered single-
domain camelid antibody (VHH), capable of neutralizing RSV at much lower antibody 
titers, linked to the DAF GPI membrane anchor sequence, termed aVHH119. Single chain 
antibodies offer several advantages over whole IgG for mRNA delivery, including: (1) they 
are much smaller than whole IgG, so that more molecules are delivered per gram of mRNA 
(2) shorter mRNAs are translated more efficiently due to increased ribosome density, and 
(3) single chain antibodies are expressed by a single mRNA and thus do not require heavy 
and light chain association to actively bind antigen121. Like aPali, the expressed aVHH was 
primarily localized to the plasma membrane in vitro, and protected cells from RSV infection 
(Figure 3.13A), as demonstrated by the quantification of the RSV N volume in either 
untransfected or transfected cells (Figure 3.13B). Importantly, the RSV N signal observed 
in cells transfected with aVHH was derived only from the initial virus inoculum; no 
detectable replication occurred in the transfected cells. Delivery of aVHH mRNA drastically 
reduced RSV titer, with 3 of the 6 replicates producing no detectable plaques (Figure 
3.13C). Additionally, aVHH mRNA transfection significantly reduced RSV F copy number 
in infected cells, by 81.8%, compared to untransfected controls (Figure 3.13D). These 
data indicate that delivery of aVHH mRNA potently inhibited RSV infections in transfected 
cells.  
Finally, to demonstrate that aVHH mRNA is also effective as a prophylactic in vivo, 
we delivered 100 μg of aVHH or aPali mRNA by intratracheal aerosol to mice lungs. One 
day later, we infected the animals with RSV L19. At 4 dpi, animals were sacrificed and 
their lungs were excised and prepared for microscopy, qRT-PCR, and plaque assay. First, 
we found that aVHH was readily detectable by immunofluorescence in transfected lungs, 
increasing in brightness from 1 day to 5 days post transfection (Figure 3.13E). Additionally, 
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aVHH mRNA delivery reduced RSV staining compared to untransfected controls at 4 dpi. 
Both RSV titer and RSV F copy number from animals treated with aVHH mRNA were not 
significantly different from mock infected mice (Figure 3.13F-G). Overall, these data 
demonstrate that (1) the GPI anchor sequence can be used interchangeably between 
whole IgG and single chain antibodies, and (2) mRNA-expressed aVHH is highly effective 





Figure 3.13. Adapting the GPI anchor to single-chain antibodies. (A) Cells were 
transfected with vehicle control or 1 μg aVHH mRNA. After overnight incubation, cells 
were infected for 24 h before being fixed and stained for RSV N (red), panRSV (blue), and 
aVHH (green). Scale bar represents 10 μm. (B) Quantification of mean volume of RSV N 
signal per cell from microscopy images in part (A). Error bars represent 95% confidence 
intervals. Asterisks indicate p<0.0001 (Mann-Whitney U test). (C) Cells were transfected 
with vehicle control or 1 μg of aVHH mRNA and infected with RSV at MOI of 0.1 before 
being analyzed by plaque assay. Error bars represent standard deviation. Asterisks 
indicate p<0.01 (Mann-Whitney U test).  (D) Cells were transfected with vehicle control or 
1 μg of either aPali or aVHH mRNA. Cells were infected with RSV for 24 h before RNA 
was isolated. Mean RSV F copy number was determined by qRT-PCR and normalized to 
the mock control group. Asterisk indicates p<0.05 (Kruskal-Wallis test, Dunn’s multiple 
comparisons test compared to mock). (E) Mice lungs were transfected with saline or 100 
μg of naked aVHH mRNA. Uninfected mice were sacrificed on days 1 and 5 post 
transfection. 1 day after transfection, mice were infected intranasally with RSV L19. Lungs 
were cryosectioned and stained for aVHH (white) and panRSV (green). Scale bar 
represents 50 μm. (F) Infected mice lung homogenate supernatants from part (E) were 
analyzed by plaque assay. Error bars represent standard deviation. Asterisk indicates 
p<0.05 (Kruskal-Wallis test, Dunn’s multiple comparisons test compared to mock). (G) 
Infected mice lung homogenates from part (E) were analyzed by qRT-PCR for mean RSV 
F copy number. Error bars represent standard deviation. Asterisk indicates p<0.05 





 To our knowledge, this study is the first instance of mRNA-based expression of 
neutralizing antibodies in the lung to prevent viral infections in vivo. We demonstrated that 
GPI-anchored mRNA-expressed antibodies are retained on the plasma membrane of 
transfected cells, and we report that expressed neutralizing antibodies with and without a 
plasma membrane anchor can prevent infections in vitro and in vivo, in an RSV model 
system. We determined that aPali inhibited RSV by preventing fusion of viral particles with 
the membrane of transfected cells. In addition, we found that mRNA-expressed 
neutralizing antibodies did not alter baseline cytokine levels, an important safety concern 
as undesirable inflammation could limit the translational application of this approach. We 
also showed that the GPI anchor is adaptable to other types of neutralizing proteins, such 
as highly-potent neutralizing VHH antibodies, where lung retention was greatly enhanced 
compared with historical half-life data for VHH antibodies.  Theoretically, since the delivery 
characteristics are based on the mRNA properties, many expressed therapeutic proteins 
could be anchored in such a manner.  
Interestingly, we found that expressing antibodies with the GPI anchor resulted in 
far less accumulation of the antibody in the ER and secretory membrane system 
compared to the secreted antibody.  As we only evaluated the DAF GPI linker, we can 
only speculate if the improved trafficking is linker specific, but it is clear that the linker 
effected the localization.  It is possible that the linker is improving antibody assembly, as 
the heavy chains may be less mobile in the lumen of the ER, promoting heavy and light 
chain interactions, and may improve trafficking to the plasma membrane117.  Future work 
will focus on linker effects on the efficiency of antibody assembly when expressed from 
mRNA.  Linkers with higher cleavage rates could be incorporated to more reliably liberate 
the antibody from the cell in cases where secretion is critical.   
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In addition, our mRNA imaging data suggested that approximately half of the 
naked mRNA, when delivered by aerosol to the lung, was free of the endosomal 
compartment, in contrast to typical nanoparticle delivery122,123, where only a small fraction 
of RNA is delivered to the cytosol. This was a surprising result, and clearly indicates that 
further research should focus on how droplet size, velocity, and buffers are facilitating 
cytosolic delivery. We did find though, that Viromer RED delivery of aPali mRNA was 
equally as effective at preventing RSV infection as naked mRNA delivery, and that in vivo-
jetPEI exacerbated cytokine responses and did not significantly reduce viral titers, 
indicating the importance of the delivery approach on outcomes and safety.   
 While previous studies have used GPI-anchored antibodies for high-throughput 
screening purposes and HIV inhibition in vitro, we report here the first use of antibodies 
anchored to the surface of cells as a prophylactic approach for lung infections124,125. 
Importantly, expressing anchored neutralizing antibodies on the surface of lung cells 
provides several benefits over systemic delivery by: (1) preventing the neutralizing 
antibody from diffusing away from the tissues infected by viruses, (2) raising the local 
concentration of antibody in the target organ, and (3) are likely increasing the time that 
neutralizing antibodies are present on the mucosal surface. Together, these benefits point 
to a prophylactic approach that has the potential to be more efficacious than systemic 
neutralizing antibody delivery, while avoiding systemic delivery. Taking into account that 
children receive 15 mg/kg of palivizumab during treatment, this could lead to significant 
cost reduction and mitigate the risk of anti-human antibody responses.  
These properties were even more important in the case of single chain antibodies. 
Single chain antibodies are smaller than whole immunoglobulins, have larger diffusion rate 
constants, and are cleared much more rapidly, with serum half-lives ranging from 30 min 
to 2 h126–128. Anchoring these small, high-affinity, neutralizing antibodies to the plasma 
membrane overcame these issues while allowing for more mRNA copies to be delivered 
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per equivalent mass. We found that aVHH mRNA delivery was highly effective at 
mitigating RSV infection both in vitro and in vivo. Critically, aVHH mRNA delivery and 
infection with RSV resulted in statistically similar data as mock infected animals by both 
plaque assay and qRT-PCR. We also demonstrated retention of the aVHH on lung cells 
5 days post transfection. Additionally, in cases where the Fc region of the antibody 
enhances neutralization of the pathogen, such as HIV, anthrax, and influenza, a sequence 
encoding the Fc could be inserted between the single-chain antibody coding region and 
the GPI anchor sequence129–132. Because they do not rely on heavy and light chain 
association, sequences encoding single chain antibodies also offer the ability to multiplex 
several anchored neutralizing antibodies in a single cocktail, either for targeting multiple 
pathogens or additional virus strains. 
Here we used RSV as a model system to test the prophylactic benefits of synthetic 
mRNA-expressed neutralizing antibodies. However, it is important to stress that mRNA 
encoding broadly neutralizing antibodies that target other viruses can be used to prevent 
infection, such as influenza or human metapneumovirus133. Additionally, the membrane 
anchor can be easily adapted to other neutralizing antibodies or proteins in cases where 
systemic antibody therapy is undesirable. Moreover, we emphasize the use of the anchor 
on single chain antibody constructs, which will allow for multivalent prophylaxis against 
additional pathogens and viral strains. Overall, pulmonary expression of neutralizing 
antibodies is a new prophylaxis tool that can protect the lung from infection and is 
adaptable to other viruses and antibodies.  
Methods 
 
Cell lines and virus culture 
Vero cells (African green monkey kidney cells, American Type Culture Collection 
CCL-81) or HEp-2 (human epithelial cells, ATCC CCL-23) were cultured in DMEM (Lonza) 
supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 100 U mL-1 penicillin and 
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100 mg mL-1 streptomycin (Life Technologies). Cells were plated on No. 1.5 coverslips 
(Electron Microscopy Sciences) one day prior to infection. Both Vero and HEp-2 cell lines 
were authenticated by ATCC and were checked for Mycoplasma contamination in our 
laboratory. HEp-2 cells are commonly used to propagate RSV in culture. 
Human RSV A2 (ATCC VR-1544) and human RSV L19 (a gift from Martin L. 
Moore’s lab, Emory University) was propagated in HEp-2 cells when the cells were >80% 
confluent. The media was removed and cells were washed with DPBS (without Ca2+ and 
Mg2+, Lonza), and virus was added at a multiplicity of infection (MOI) of 0.1 for 1 h before 
adding complete medium to the inoculum. Cell-associated virus was harvested by 
scraping the cells when about 90% of cytopathic effects was visualized (about 96 hpi). 
Virus was then vortexed briefly, aliquoted, and stored at -80 ºC. For L19 virus, the cell 
suspensions were sonicated at 30% amplitude, with 1 second on/off pulses and 
centrifuged at 800x g at 4 °C. Supernatants were pooled and 1mL aliquots were snap 
frozen in liquid nitrogen and stored at -80 ºC. Virus titers were measured via plaque assay. 
Antibodies 
For immunostaining, primary antibodies used were mouse anti-RSV N (Abcam, 
Cat. No. ab22501), mouse anti-RSV G (Abcam, Cat. No. ab94966), rabbit anti-camelid 
VHH (GenScript, Cat. No. A01860-200), goat anti-panRSV polyclonal (Millipore, Cat. No. 
AB1128), rat anti-CD63 (BD, Cat. No. 564221), rabbit anti-Rab5 (Affinity BioReagents, 
Cat. No. PA3-915), and rabbit anti-Rab7 (Abcam, Cat. No. 137029). All primary antibodies 
for immunostaining experiments were used at 1 µg/mL. Secondary antibodies used were 
donkey anti-human Alexa Fluor 647 (Jackson ImmunoResearch), donkey anti-goat Alexa 
Fluor 546, donkey anti-rabbit Alexa Fluor 488, and donkey anti-mouse Alexa Fluor 488 
(all from Life Technologies). All secondary antibodies for immunostaining experiments 
were used at 4 µg/mL. For dSTORM experiments, secondary antibodies used were 
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donkey anti-mouse Alexa Fluor 647 (Life Technologies) and goat anti-human CF568 
(Biotium), and both were used at 1 µg/mL.  
Construct preparation for in vitro transcription 
Plasmids for IVT were designed using the full length nucleotide sequences of 
palivizumab heavy and light chain. The coding region was preceded by 5’ UTR with Kozak 
sequence and followed by a 3’ untranslated region (UTR) derived from the mouse alpha 
globin sequence. Sequences were human codon optimized and inserted in a pMA-7 vector 
(Thermo Fisher Scientific, GeneArt) to be used as a template for mRNA synthesis. For the 
anchored version of palivizumab, a GPI linker based on the human decay accelerating 
factor (DAF) was appended to the Fc region of the heavy chain and synthesized in the 
same manner as the secretory version134. 
V5 peptide tag addition (PCR) 
V5 is a 14 amino acid epitope tag that was inserted into the 3’ terminus of the light 
chain construct through two fragment Gibson assembly. The linear backbone was PCR 
amplified from the insertion site in the forward and reverse directions (primers 1 and 2, 
Table 3.1). The insert was 104 bp in size – 42 bases for the V5 tag and 31 x 2 bases for 
the overlapping segments that correspond to the aPali light chain backbone. This insert 
was synthesized via PCR (primers 3 and 4, Table 3.1). All PCR products were 0.8% 
agarose gel purified.  
The backbone was assembled with 3x molar excess of insert in 5 µL total volume 
of NEBuilder® HiFi DNA Assembly Master Mix, according to NEB’s protocol. After 
incubation for 1 hour at 50C, 1 µL of reaction mixture was used to transform NEB 5-alpha 
competent E. Coli. Ampicillin plates were used to select 10 colonies and outgrowth 
performed at 30C for 24 hours. Subsequent plasmids from each colony were Sanger 
sequenced to ensure incorporation of the V5 tag at the 3’ terminus of the light chain. 
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Immunofluorescence staining confirmed that V5 tag insertion did not negatively impact 
heavy and light chain association or ability to knock down RSV infection.  
Gibson assembly of aVHH construct 
The anchored VHH sequence, F-VHH-4 from Rossey et al., flanked by UTRs, was 
ordered as a DNA geneblock from IDT119. The geneblock was PCR amplified with primers 
that contained overlapping regions for the PMA-7 vector (primers 5 and 6, Table 3.1). This 
aVHH PCR product was cloned into the PCR amplified pMA7 vector (primers 7 and 8, 
Table 3.1) through Gibson assembly using NEB Builder with 3x molar excess of aVHH 
insert, as described above. All reaction transcripts were 0.8% agraose gel purified prior to 
assembly reaction. Subsequent plasmids from each colony were Sanger sequenced to 




Table 3.1. Primers used for construct synthesis and PCR. All sequences are 
presented in 5’ to 3’ direction. *These sequences are from Mentel et. al.135. 
  
Primer 1 
Forward Primer for 




Reverse Primer for 
pMA7:VHH LC at 3' end 
insertion site 
GCACTCGCCCCGGTTGAAGCTCTTGGTCACG 
Primer 3 Forward Primer to create insert with V5 tag 
CGTGACCAAGAGCTTCAACCGGGGCGAGTGCGGCAAG
CCCATCCCCAACCCCCTGCTGGGCCTGGACAGCACCTG 




Forward Primer to place 
pMA7 overlaps on 5' end 




Reverse  Primer to place 
pMA7 overlaps on 5' end 
of VHH geneblock 
CGGGCAGTGAGCGGAAGGCCCATGAGGCCCAGTTTTTG 
Primer 7 
Forward Primer for to 




Reverse Primer for to 
amplify linear pMA7 PCR 
product 
GGCCTTCCGCCAATCGTC 
Primer 9 RSV F gene (standard) Forward CTTTCTTCCCACAAGCTGAAAC 
Primer 10 RSV F gene (standard) Reverse GTGGTGGATTTACCAGCATTTAC 
Primer 11 RSV F-qPCR Forward* AACAGATGTAAGCAGCTCCGTTATC 
Primer 12 RSV F-qPCR reverse* CGATTTTTATTGGATGCTGTACATTT 






Synthetic mRNA in vitro transcription 
Plasmids were linearized with Not-I HF (New England Biolabs) overnight and PCR 
purified using PCR clean-up kit (Qiagen), prior to in vitro transcription (IVT) using a T7 
mScript kit (Cellscript) following the manufacturer’s instructions. Equimolar ratios of ATP, 
GTP, and CTP were used alongside N1-methylpseudouridine-5’-triphosphate (TriLink). 
RNAs were capped using 2’-O-Methytransferase followed by enzymatic addition of a poly-
A tail, both according to the mScript kit instructions. The capped and tailed mRNAs were 
then purified using an RNeasy kit (Qiagen) and treated with Antarctic Phosphatase (New 
England Biolabs) for 1 hour (New England Biolaboratories), and purified again. RNA 
concentration of the purified mRNA was measured the RNA was stored at -80 °C until 
further use. 
Transfections in vitro 
Vero cells were transfected using either Viromer Red (Lipocalyx) or Neon electroporation 
system (Invitrogen), according to the manufacturer’s instructions, into a 24 well plate (for 
imaging and plaque assays) and were transfected with 1 µg of mRNA per 200,000 cells. 
For mRNA encoding whole IgG, heavy chain and light chain mRNAs were combined in a 
4:1 mass ratio for equimolar conditions. Twenty hours post-transfection, cells were fixed 
and immunostained with or without permeabilization. 
Immunostaining 
Vero cells were fixed with 4% paraformaldehyde (PFA) (Electron Microscopy 
Sciences) for 10 min at room temperature before permeabilization with 0.2% Triton X-100 
(Sigma) for 5 min at room temperature. Then, cells were blocked by incubation with 5% 
bovine serum albumin (Calbiochem) for 30 min at 37ºC before being incubated with 
primary antibody for 30 min at 37 ºC. Cells were then washed with PBS and incubated 
with secondary antibody for 30 min at 37 ºC. Multiple antibody labeling was performed 
simultaneously after checking cross-reactivity. Nuclei were then stained with 4’,6-
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diamidino-2-phenylindole (DAPI) (Life Technologies), and coverslips were mounted onto 
glass slides with Prolong Gold (Life Technologies). 
Plaque assay 
For mRNA knockdown of viral titer in vitro, Vero cells were transfected with or 
without aPali or aVHH mRNA, using the Neon system, into a 24 well plate and incubated 
until fully confluent. Either 50 µL of serially diluted lung supernatant (for in vivo studies) or 
50 plaque forming units (PFU) or multiplicity of infection (MOI) of 0.01, 0.1 or 1 (for direct 
measurements or supernatant measurements, respectively) of RSV A2 stock was added 
to the cells. Cells were incubated at 37 ºC for 1 h with shaking every 15 min. At 1 hpi, 1 
mL of overlay media, consisting of either 1.2% Avicel (FMC Biopolymer) or 1.2% 
methylcellulose (Sigma-Aldrich) in 1X DMEM with 2% FBS and 100 U mL-1 penicillin and 
100 mg mL-1 streptomycin (Life Technologies), was added. At either 6 dpi (RSV for A2) or 
8 dpi (for RSV L19), cells were washed and fixed with 4% paraformaldehyde, blocked with 
5% BSA, and stained with a goat anti-panRSV polyclonal and HRP-conjugated donkey 
anti-goat secondary antibody. A precipitating peroxidase substrate (TrueBlue, KPL) was 
then added and cells were incubated at room temperature for 10 min before a final wash 
with water. Plaque count was converted using the dilution factor to generate viral titer in 
PFU/mL and, in the case of in vivo assays, lung titers were normalized by lung weights. 
Animal studies 
Six- to 8-week-old female BALB/c mice (Charles River Laboratories) were 
maintained under pathogen-free conditions in individually ventilated and watered cages 
kept at negative pressure. Food was provided to mice ad libitum. Animals were 
acclimatized for at least 6 d before the beginning of experiments. Animals were sacrificed 
by CO2 asphyxiation. Infected animals were handled and kept under BSL-2 conditions 
until euthanized. All animals were cared for according to the Georgia Institute of 
Technology Physiological Research Laboratory policies and under ethical guidance from 
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the university’s Institutional Animal Care and Use Committee (IACUC) following National 
institutes of Health (NIH) guidelines. Number of animals used in each experiment is 
detailed in Table 3.2. 
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Table 3.2. Number of animals used per experiment 
Experiments Groups No. of animals per group 
Total animals per 
experiment 
aPali Expression using 




PEI, Naked mRNA 
3 each 15 
mRNA titration Control, 20 µg, and 100 µg 
3 control, 4 each 
amount 11 
Palivizumab 680 Control and Palivizumab 3 each 6 
mRNA distribution in 
lung Control and aPali 2 each 4 
aPali expression using 
Flow Cytometry Control and aPali 1 control, 3 aPali 4 
RSV Challenge 
Control, RSV only, aPali, 
aPali+RSV, sPali, 
sPali+RSV, 
10 (8 for RSV 
titers and 2 for 
microscopy) 
60 
aVHH expression Control, aVHH, and aVHH+RSV 2 each 6 
aVHH Challenge 
Control, RSV, aPali, 
aPali+RSV, aVHH, 
aVHH+RSV 
3 each 18 






Palivizumab intramuscular injection 
Mice were anesthetized under constant isofluorane (Henry Schein Medical) with 
oxygen and kept on a heating pad. The anterior tibialis muscle was then shaved and 
injected with 15 mg/kg of palivizumab in 25 µL using a 29 gauge needle. Near-IR imaging 
was performed using a Fluobeam (Fluoptics) on anesthetized mice. Mice were euthanized 
24 h post injection and organs were imaged for palivizumab biodistribution in organs pre- 
and post- harvesting using the Fluobeam. 
Intratracheal aerosol mRNA transfections 
Mice were anesthetized using 87 mg/kg ketamine and 16 mg/kg xylazine. The 
trachea was visualized by inverting the mouse on a 45° tilting intubation stand (Hallowell 
EMC) using the upper teeth and illuminating the trachea with a flex light. A 1.22 mm 
endotracheal tube (ET, Hallowell EMC) was then inserted to intubate the animal. A 
MicroSprayer Model IA-1C connected to a High Pressure Syringe Model FMJ-250 (both 
from PennCentury) was then inserted such that the tip of the sprayer nozzle was 1 mm 
past the tip of the ET tube. The MicroSprayer was then actuated using a custom Pump 11 
Elite Nanomite handheld syringe pump (Harvard Apparatus) that allowed for repeatable 
pressure and volume delivery of 50 µL. To find the best delivery vehicle, we compared 
Viromer RED and in vivo-jetPEI against naked mRNA at 40 μg in nuclease free water. For 
naked mRNA transfections, the appropriate amount of mRNA was mixed with water to the 
desired concentration. For Viromer RED transfections, 0.2 μL of Viromer RED (Lipocalyx) 
per 1 µg of mRNA was mixed with Buffer Red. The mRNA, also diluted in Buffer Red, was 
then added to the Viromer solution, per the manufacturer’s instructions. For in vivo-jetPEI 
transfections, 40 μg of mRNA was delivered with 6.4 μL of vehicle diluted in 5% glucose 
in water. In order to mitigate any possible double stranded RNA-dependent protein kinase 
(PKR) response, Imidazolo-oxindole PKR inhibitor C16 (Sigma-Aldrich) was added to all 
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mRNA preparations to a final concentration of 375 μM. To find an optimum mRNA amount 
for delivery, we tested aPali at 20 μg and 100 μg without any delivery vehicle. 
MTRIP labeling of mRNA 
MTRIPs were constructed as described previously93,97,120. Briefly, we designed four 
2’ O-methyl RNA-DNA chimeric oligonucleotides, each containing a 17-18 nucleotide 
binding region and 5-7 poly(T) linker. Oligos were complementary to 4 adjacent sequences 
across the mRNA 3’ UTR regions and contained 3-4 amino-modified thymidines each, as 
well as a 5’ biotin modification (Biosearch Technologies). Labelled oligos were 
synthesized by conjugating either Cy3B NHS ester (GE Healthcare) or DyLight 650 
(Thermo Fisher) to the amine groups on the oligonucleotides following the manufacturer’s 
protocol. Complete MTRIPs were assembled by incubating the labeled oligos with 
Neutravidin (Pierce) for 1 h at RT followed by filtration using 30 kDa MWCO centrifugal 
filters (Millipore). mRNA was buffer exchanged into 1X PBS, heated to 70 ºC for 10 min, 
and immediately placed on ice. Denatured mRNA was then combined with MTRIPs in a 
1:1 ratio for each MTRIP and incubated at 37 ºC overnight. Labeled mRNA was then buffer 
exchanged into water and concentrated using a 30 kDa filter before being injected into the 
animals.   
RSV infections in mice and tissue processing 
One day after transfection, mice were anesthetized using cotton soaked with 
isofluorane in a small chamber. After breathing rate had slowed sufficiently, mice were 
inoculated with 5x105 PFU of RSV L19 in 50 µL, with 25 µL in each nostril. Mice were 
weighed before infection and then once daily to monitor weight loss. Mice were sacrificed 
by CO2 asphyxiation at 4 dpi. Lungs were harvested in cold DMEM without any 
supplements and were either stored on ice for imaging or snap-frozen in liquid nitrogen 
for protein and RNA extractions. Snap frozen tissues were thawed and homogenized 
using a Gentle MACS Tissue Dissociator (Miltenyi) and centrifuged to collect supernatants 
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for plaque assay and cytokine analysis. Tissue pellets from this step were used for RNA 
extraction.  
For plaque assay, neat and serially diluted lung homogenates were added to 
confluent Vero cells and processed as described above. Dilutions with individual plaques 
were counted and averaged across 4 replicate wells to generate viral titer in PFU/mL. Viral 
titer was then normalized by lung weight.  
Lung tissues collected in DMEM were washed in PBS and fixed in 4% 
paraformaldehyde overnight. Tissues were then washed three times in PBS and were 
cryoprotected using 30% sucrose (Sigma) in 1X PBS until tissues sank to the bottom of 
the container. Tissues were then frozen in OCT compound (Tissue-Tek) and 
cryosectioned (10 µm sections). Tissue sections were then immunostained as described 
above. 
Flow cytometry 
Mice lungs were collected in DMEM and washed to remove any blood. The tissues 
were then dissociated using the Miltenyi Lung dissociation kit, following manufacturer’s 
instructions with slight modifications136,137. Briefly, after coarse digestion of lungs, 0.1 
mg/mL soybean trypsin inhibitor (Sigma) 60 U/mL DNAse I and 1mg/mL type XI 
collagenase was added and tissues were digested at 37°C for 30 min. Then, lungs were 
finely homogenized in Miltenyi Gentle MACs, followed by addition of 0.1 M EDTA in FBS 
to inactivate the enzymes. Cell suspension was then passed through 70 μm filter, washed 
with PBS by centrifugation at 800 xg for 10 min. RBCs were lysed using ACK lysis buffer 
(Alfa Aesar) and washed with DPBS. Cells were then counted and 1-2 million cells were 
stained with live/dead marker (Life Technologies) before being incubated with rabbit anti-
V5 antibody followed by AlexaFluor 488 conjugated donkey anti-rabbit secondary antibody 
(Invitrogen). Cells were then fixed with BD Cytofix/Cytoperm (BD Biosciences) and 
acquired on a BD LSRFortessa flow cytometer. Compensation was performed using 
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beads (BD Biosciences) labeled with fluorophore conjugated antibodies.Data was 
analyzed using Flow Jo software (Treestar). 
qRT-PCR 
Total RNA was extracted from cells or tissues using an RNeasy kit (Qiagen) and 
cDNA was synthesized using 250 ng of total RNA and a High Capacity cDNA synthesis 
kit (Applied Biosystems) with random hexamers. Extent of RSV infection was assessed 
using an absolute quantification method based on RSV F gene copy numbers as 
described previously135. Primers used are in Table 3.1. For cytokine analysis, Taqman 
gene expression assays were used for IL-6, IFN-β, IFN-γ, and CCL5 (Thermo Fisher).  
Bead-based immunoassay 
Lung homogenates were assessed for cytokine response using a custom Millipore 
Milliplex assay following the manufacturer’s instructions. Briefly, samples were diluted 1 
fold in assay buffer and assayed using a BioPlex 2.0. Observed and interpolated cytokine 
concentrations were used and undetected cytokines were set as 0.1 pg/mL.  
Microscopy 
 
All images were acquired with a Hamamatsu Flash 4.0 v2 sCMOS camera on a 
PerkinElmer UltraView spinning disk confocal microscope mounted to a Zeiss Axiovert 
200M body with either a 63x NA 1.4 plan-apochromat objective for individual cells or a 
20X NA 0.8 plan-apochromat objective for tissue sections. All 63x images were acquired 
with Volocity (PerkinElmer) with Z-stacks taken in 0.2 µm increments. Stitched tissue 
images were acquired automatically using the motorized ASI PZ-2150 stage in Volocity 
using 25% overlap with automatic alignment and without background correction. Linear 
contrast enhancements were applied to images for clarity. Unless indicated, all images in 
a given experiment were enhanced the same. All image quantification and analysis was 




Images were acquired using a Bruker Vutara 352 with a 63x NA 1.2 plan-
apochromat water immersion objective lens kept at room temperature. Samples were 
immunostained as above, but without nuclear counterstain since the 405 laser is used for 
dSTORM excitation. Samples were imaged in a buffer to enhance fluorophore blinking 
which contains: 50 mM Tris-HCl (pH 8.0), 10 mM NaCl, 10% glucose, 20 mM cysteamine, 
1% 2-Mercaptoethanol, 169 AU/mL glucose-oxidase, and 1,404 AU/mL catalase. Imaging 
buffer was prepared fresh daily and replaced after approximately 2 h. All images were 
acquired and analyzed using the Vutara SRX software. All images were processed using 
the denoise option set to 0.2. For particle height quantification, a 1 µm square around each 
individual particle was analyzed. To ensure quantification of RSV virions, particles were 
only included if the XY FWHM was greater than 50 nm and the Z FWHM was greater than 
100 nm. The mean of the aPali signal and mean of the RSV N signal was subtracted to 
determine mean particle distance above the aPali signal.  
Statistical analysis 
Results were plotted and statistical analyses were performed using Prism 7 











The work presented here discovered new avenues of RSV biology and 
prophylaxis, but also inspired many new questions. This chapter will review the 
accomplishments of this work and some of the future research enabled by the findings. 
These perspectives will be divided into several broad categories: enabling high resolution 
RSV G imaging, RSV G interactome analysis, and mRNA delivered anchored neutralizing 
antibody prophylaxis and treatment. 
Enabling high resolution RSV G imaging 
 
 First, we discovered that lectin conjugates can specifically bind RSV G on both 
infected cells and virions, and we found that this binding does not inhibit either infectivity 
or replication of the virus. We then used fluorescent lectin conjugates to obtain the first 
live images of wild-type RSV filament formation in cells, discovering that this process is 
microtubule, and specifically dynein, dependent. We found that many of the viral proteins 
involved with RSV assembly of mature virions colocalize with vesicles involved in filament 
formation. We observed that, during endosomal recycling, RSV G is first bound to clathrin 
during endocytosis, but is associated with caveolar membranes in mature virions. Finally, 
we recorded, for the first time, that RSV genomic RNA is loaded into extended RSV 
filaments, and that this process is also governed by microtubules. Together, these results 
indicate that RSV filament formation is not exclusive to the plasma membrane.  
While we demonstrate that RSV filaments can be formed intracellularly, we also 
show that these same filaments protrude out of the plasma membrane during late-stage 
infections. Our current results do not provide a mechanistic answer for this process, but 
the first step in providing an explanation for filament translocation to the plasma membrane 
is understanding the orientation of RSV G on intracellular filaments. We could not directly 
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determine this partially due to the limited resolution of diffraction-limited confocal 
microscopy. Therefore, we began efforts to enable high resolution imaging of RSV G. First, 
we began the process of using gold nanoparticle lectin conjugates to employ cryoEM. The 
single-nanometer resolution of cryoEM, should provide enough resolution to observe 
lectin-Au labeled RSV G molecules. Obvious extensions of this method include using dual-
labeled lectins, with fluorophores and gold nanoparticles on the same lectin molecule, to 
enable Cryo-CLEM (correlated light and electron microscopy). Cryo-CLEM allows for 
samples to be investigated first using fluorescence, to obtain the general spatial and 
temporal location of interest, followed by electron microscopy, to generate the high 
resolution structural data29,138.  
 By enabling high-resolution cryoEM imaging of RSV G, we can observe other 
points along the RSV life cycle. For instance, the precise entry mechanism of RSV is still 
debated. Some reports indicate that direct fusion of virions with the plasma membrane is 
responsible139,140. Yet, other studies indicate that clathrin-mediated endocytosis is involved 
with viral uptake81,82,141. Finally, a recent study proposed that a micropinocytosis 
mechanism is implicated142. By labeling virions with lectin-Au conjugates, cryoEM can be 
utilized to observe the entry mechanism of RSV in cells with wild-type virus and minimal, 
if any, chemical fixative and permeabilization artifacts.  
Finally, in an effort to minimize risk in the event that cryoEM is unfeasible, we will 
assess the use of dSTORM to localize RSV G on cells. While the lateral resolution of 
dSTORM is only 20-30 nm compared to ~1 nm in the case of cryoEM, the increased 
resolution over diffraction-limited microscopy might be sufficient to visualize the 
populations of RSV G beneath the plasma membrane. Unlike other imaging techniques 
such as STORM, which relies on photoswitchable dyes, and FPALM, which relies on 
photoswitchable fluorescent proteins, dSTORM can be used with conventional 
fluorophores34,143,144. The switching characteristics of several conventional dyes, such as 
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Alexa Fluor 647, has already been characterized145. Additionally, the Vutara dSTORM 
system used in this work is equipped with a biplane module, which allows for enhanced 
axial resolution (~50 nm) and the ability to localize individual fluorophores in multiple 
imaging planes146. In order to first assess the ability of the dSTORM system to localize 
RSV G, we will perform initial experiments using RSV infected cells and RSV G transfected 
cells in order to verify that SBA would be suitable for further experiments.  
To these ends, we attempted: 1) adapting SBA to cryoEM by generating gold SBA 
conjugates and optimizing cell infection and staining conditions, and 2) using fluorescent 
SBA conjugates to label RSV G on infected cells and on cells transfected with RSV G 
mRNA (cells thin enough to enable cryoEM imaging).  
First, while RSV G localization has been characterized in infected cells using 
transmission EM (TEM), there have not been any reports of RSV G imaging using cryoEM. 
Though TEM imaging of RSV first indicated that virion assembly can occur prior to the 
plasma membrane and that RSV G is present along the membranes of intracellular 
vesicles, the precise mechanism governing the translocation of progeny from the 
intracellular space to the plasma membrane has not been delineated21. This is likely due 
to the chemical fixatives and permeabilization techniques required for adequate gold 
labeling in TEM147. Because these chemical-based techniques can result in a loss of 
ultrastructure, cryogenic freezing of cells is utilized which can maintain structural integrity, 
resulting in the most accurate representation of cells148–150. However, gold labels in 
cryoEM must be applied to living cells, so intracellular staining can be difficult151. Because 
RSV G recirculates, and SBA can be applied to the extracellular fraction and allowed to 
internalize, this method could be used alongside a gold-conjugated SBA (SBA-Au) in order 
to visualize the intracellular localization of RSV G using cryoEM. To begin testing this 
theory, we first characterized the conjugation of gold nanoparticles to SBA, ensuring that 
the process did not inhibit the binding of SBA-Au to RSV G. Additionally, in order to confine 
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sample thickness to the 500-700 nm limit of cryoEM, cell plating strategies, infections, and 
lectin labeling was assessed prior to attempting cryoEM.  
Characterizing the conjugation of gold nanoparticles to SBA 
 
First, we purchased commercially available SBA-Au containing either a 5 or 10 nm 
gold nanoparticle. When analyzed by high performance liquid chromatography (HPLC), 
we found that while some SBA-Au samples were quite pure, indicated by a single sharp 
peak in the chromatogram, others were not, indicated by a broad plateau (Figure 4.1). 
Because of the variation in SBA-Au purity, we opted to only use either commercially 
available SBA-Au that had been verified by our HPLC or SBA-Au conjugates that we 
produced and purified ourselves.  
 
Figure 4.1. Commercially available Au-SBA conjugates vary in purity. 5 (blue) and 10 
nm (red) Au-SBA conjugates were analyzed by size-exclusion HPLC. Note that a sharp 




Next, we verified that conjugation of gold nanoparticles to SBA does not inhibit the 
binding of SBA to RSV G. First, we labeled individual RSV virions with SBA-Au and 
isolated them onto glass coverslips. The RSV particles were then fixed and 























08052016 SBA 10nm EY  Labs 50uL.lcd Detector A Ch1
08052016 SBA 5nm EY  Labs 50uL.lcd Detector A Ch1
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immunostained for RSV F. Localization of gold nanoparticles was then visualized using 
darkfield microscopy while the immunostained viral proteins were imaged using the 
widefield epifluorescence light path on the same instrument. We observed that SBA-Au 
bound to the isolated RSV virions, allowing clear visualization of the viral filaments, though 
some lectin-gold conjugate bound the glass coverslip nonspecifically (Figure 4.2A). 
Finally, we ensured that SBA-Au binds RSV G on infected cells. Vero cells were infected 
for 24 h with RSV A2. Cells were labeled live with SBA-Au before being fixed and 
immunostained for RSV F and RSV G. Again, cells were imaged using darkfield and 
widefield epifluorescent microscopy. While some background SBA-Au staining is present 
on the cells, RSV filaments are visibly demarcated in the darkfield channel, indicating that 




Figure 4.2. SBA-Au labels RSV G.  (A) Gold-SBA (red) was incubated with RSV A2 
stocks for 30 min before filaments were isolated onto glass coverslips. Isolated virions 
were fixed and stained for RSV F (green). Cropped regions are indicated by the white 
boxes.  (B) Vero cells were infected with RSV A2 for 24 h before RSV G was labeled live 
with gold-SBA (red). Cells were then fixed and immunostained for RSV F (blue) and RSV 




The effect of cell plating density and infection technique on RSV morphology 
 
Since cryoEM requires very thin specimens, the technique requires plating cells in 
a very sparse manner29. First, we assessed the effect of cell plating density on RSV 
structures. Vero cells were plated at either low or high confluence, infected with RSV A2 
for 24 h, and labeled live with SBA-488 immediately prior to fixation. Cells were then 
immunostained for RSV F and RSV N. Cells infected at high confluence exhibited many 
long viral filaments composed of RSV G, RSV F, and RSV N. However, cells infected at 
low confluence had much fewer filaments per cell, and the filaments often did not contain 
one or more of the stained viral proteins (Figure 4.3). As a first attempt at resolving this 
issue, we infected confluent cells for 24 h before trypsinizing the cells to lift them off the 
surface and plating the infected cells at either low or high confluence onto new coverslips. 
After several hours, cells were labeled with SBA before being immediately fixed and 
immunostained for RSV F and RSV N. When infected and plated in this manner, long RSV 
filaments were visible that contained all of the stained RSV proteins, as expected (Figure 
4.3). These infection and plating conditions should be further assessed and used in future 




Figure 4.3. Reseeding RSV infected cells preserves prototypical RSV 
structures. (TOP) Vero cells were plated at high and low density and infected for 24 hours 
with RSV A2 at MOI 1. At 24 hours, cells were either labeled with SBA-488 (green), and 
fixed and stained for RSV F (blue) and N (red). (BOTTOM) Vero cells were plated at high 
density and infected for 24 hours with RSV A2 at MOI 1. Cells were trypsinized and 
reseeded at high and low density. After 2 hours, cells were labeled with SBA-488 (green) 




RSV G glycosylation moieties vary by cell type 
 
 As mentioned several times already, cryoEM necessitates very thin specimens. In 
order to accommodate this requirement, certain cell lines are often chosen for having a 
low average thickness152. For RSV, several cell lines have already been evaluated for 
cryoEM based on permissivity of the virus and thickness29. Additionally, glycosylations 
present on RSV G have been shown to be highly cell type dependent153. We assessed 
the binding of various fluorescent lectin conjugates to RSV G on infected A549 and Beas-
2B cells, two cell lines often chosen for RSV work and compatible with cryoEM. Cells were 
infected with RSV, incubated for 24 h, and stained live with either SBA, helix pomatia 
agglutinin (HPA), wheat germ agglutinin (WGA), or concanavalin a (ConA), all conjugated 
to Alexa Fluor 488. Cells were then fixed immediately and imaged. Unlike the Vero and 
HEp-2 cell tested in Chapter 2, SBA, WGA, and ConA all had high background staining 
on mock-infected A549 cells, while HPA-488 specifically bound infected cells with minimal 
background on mock-infected controls (Figure 4.4). When lectin binding to RSV G was 
analyzed on infected Beas2B cells, all of the tested lectins exhibited high background 
staining on mock infected cells (data not shown). These data indicate that: 1) glycosylation 
of viral proteins is highly variable by cell type and 2) HPA conjugates should be used on 





Figure 4.4. HPA-488 specifically bind RSV G on infected A549 cells. A549 cells were 
infected with RSV A2 for 24 h before being labeled live with the indicated 488-conjugated 




Our methods for adapting lectin labeling to cryoEM techniques should enable single 
nanometer resolution imaging of RSV G structures in infected cells. The results of these 
experiments have generated a list of criteria that must be met for cryoEM imaging. First, 
the lectin-gold conjugate must be pure (as analyzed by HPLC) in order to minimize 
background due to nonspecific binding. Second, the cell types used in cryoEM imaging of 
RSV infected cells should be individually tested for lectin binding using a panel of 
fluorescently conjugated lectins. This will allow selection of a compatible cell type and 
lectin marker for RSV G labeling. Third, before proceeding to infection staining, cells 
should be transfected with RSV G and imaged with the selected lectin under cryoEM. This 
will ensure that the staining is specific with minimal background on untransfected cell lines. 
Last, the chosen lectin can then be used to image RSV G on infected cells, with discretion 
used on infection technique to minimize alteration of the progeny virion morphology. 
Future work could include ensuring the lectin-gold conjugates do not inhibit RSV infectivity 
or replication as well as ensuring the lectin-gold conjugates are endocytosed in a similar 
manner to the fluorescent counterparts154. Finally, once all lectin-gold conjugate binding 
verification is complete, cryoEM on both transfected and infected cells could be performed.  
 By using SBA-488 on live RSV G transfected or RSV infected cells, we will be able 
to examine the localization of the glycoproteins during infections and in a reduced system. 
This work opens a new avenue to study the interactions and localizations of RSV G, both 
in the cytoplasm and at the membrane, with other RSV proteins such as RSV F, RSV N, 
and RSV M. Additionally, the reduced mRNA-based system could be studied in further 
detail, with various combinations of viral proteins expressed, in order to examine their 
individual effect on RSV G localization and trafficking to the plasma membrane. The role 
of clathrin and caveolar membranes is still actively being studied with regard to RSV 
replication and assembly26,154. Therefore, in both the reduced systems and viral infections, 
the interactions and localizations of clathrin and caveolin with RSV G can be studied using 
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dSTORM alongside interaction assays such as proximity ligation assay (PLA), that we 
have previously utilized98,120,155–157.  
RSV G interactome analysis 
 Our ability to label RSV G on infected cells and RSV particles also provides the 
capability to analyze the dynamics of RSV G during all stages of an infection. Additionally, 
by employing a combination of colocalization analysis, dSTORM, and PLA (proximity 
ligation assay) interaction assays, we can track the location of RSV G as well as host cell 
and viral components that interact with RSV G throughout an infection. First, the precise 
host cell proteins involved in the entry of RSV have been widely debated. By labeling RSV 
with lectin conjugates, we can investigate the interactions of RSV G with various host cell 
proteins using the methods discussed above. Confirmatory experiments with drugs to 
knock down specific pathways could be used to exactly delineate the RSV entry process. 
 The precise dynamics of RSV G during the replication stages of RSV have never 
been studied outside of our work here. We showed the RSV G recirculates from the 
plasma membrane, but the specific proteins and mechanisms involved with incorporating 
RSV G into mature filaments are not known. Currently, we hypothesize that the switch we 
observed in colocalization of RSV G from clathrin to caveolae plays a role in this 
maturation, especially as mature RSV particles contain caveolae26,154. Using lectins to 
label RSV G and investigate these mechanisms using dSTORM and PLA, along with 
pharmacological knockdown of specific cellular pathways, could answer crucial questions 
regarding the dynamics of RSV G during the RSV life cycle. By employing dSTORM and 
PLA to visualize the spatial distribution and interactions of other RSV proteins (such as 
RSV M, RSV N, RSV F, and RSV M2-1) with each other and with various host cell 
components, the complete interactome of RSV G and other viral proteins can be mapped 
across the course of an infection. Moreover, our work on expressing RSV G and RSV F 
from mRNA can be further expanded upon to help answer these questions in a more 
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discrete manner. Additional mRNAs encoding for RSV M, RSV N, RSV L, and RSV M2-1 
could be easily synthesized. Transfecting cells with one or more of the mRNAs could then 
answer very important questions regarding the individual actions of each protein. 
Specifically, expressing RSV G alone or with a combination of other viral structural 
proteins, such as RSV F or RSV M, and tracking the location of RSV G throughout its 
production, could help determine if RSV G recycling is independent or if it requires other 
viral components. Moreover, the interactions of these individual viral proteins can be 
quantified using PLA independently from a complete viral infection. Using a combination 
of whole virus and the mRNA reduced system, the interactome of RSV G can be isolated 
and studied in detail, potentially leading to new therapeutic targets. 
mRNA delivered anchored neutralizing antibody prophylaxis and treatment 
 
 Finally, we engineered mRNA expressed membrane anchored antibodies that 
prevent RSV infections in mice lungs. The broad achievement is underscored by several 
other accomplishments which will be further discussed below: 1) encoding a GPI 
membrane anchor into antibodies appears to enhance the trafficking of antibodies to the 
cell surface, 2) mRNA diluted in water can be effectively delivered to epithelial cells at 
mucosal surfaces, 3) anchoring neutralizing antibodies to the plasma membrane of 
transfected cells can protect the cell from infection, 4) anchoring antibodies results in 
increased clearance time, 5) the anchor can be easily encoded to other constructs, and 
6) anchoring single-domain VHH camelid antibodies can overcome the single major hurdle 
of an exceptionally short half-life. 
   First, we found that mRNA-expressed aPali proceeded to the surface of 
transfected cells in as little as two hours with intracellular antibody staining becoming 
undetectable 12 hours post transfection. However, sPali was visible throughout the 
secretory membrane system across all tested time points, up to the 24 hours post 
transfection. Since the structure of the GPI anchor acts as a cellular active transport signal 
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to the plasma membrane, broadly reviewed in Muñiz et. al., this could be further exploited 
to increase transport of the therapeutic protein to the plasma membrane158. Once 
trafficked to the membrane, the protein could either be retained or cleaved for secretion 
as necessary depending on the mechanism of action of the therapy, depending the choice 
of GPI anchor159.  
 Second, we found that mRNA diluted in water effectively transfected alveolar cells 
throughout the lungs of mice. This is a critical observation in the context of storage and 
“off-the-shelf” availability of future commercially available mRNA therapies. The 
hypothetical drug could be stored lyophilized in sealed anoxic vials with minimal long-term 
degradation, even in climates with elevated temperatures69. Also, the ability of mRNA to 
transfect cells in vivo via aerosol without a delivery vehicle cannot be understated. 
Critically, lack on a vehicle should be a boon for safety – while lipid nanoparticles can 
cause inflammation and long-term liver toxicity, water mixed with mRNA has no such 
issue160. In the case of pulmonary aerosol delivery, this is even more important, as 
inflammation in the airways of the lung can be life threatening. Additionally, other important 
mucosal surfaces, such as the female reproductive tract, rectum, and oral cavity, could be 
tested for efficient transfection of aerosolized mRNA without a delivery vehicle. The 
delivery of mRNA via aerosol also opens new questions on the mechanisms of droplet-
mediated RNA entry. Several aerosol characteristics could be evaluated in order to further 
optimize gene transfer in the lung epithelium including: droplet size, droplet velocity, and 
the angle of conical spraying.  
 Third, we discovered that anchoring neutralizing antibodies to the surface of the 
cell abrogates viral infection by preventing entry of virions. Broadly neutralizing antibodies 
are a promising technology in future prophylaxis, but palivizumab represents the only 
available preventative therapy. While cost is a major factor, repeated injections and a high 
neutralizing concentration required at the target mucosal surface are substantial 
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obstacles161,162. Linking neutralizing antibodies to the plasma membrane of the target 
epithelium of a particular virus can provide increased concentration of the antibody at the 
viral target surface. Clearly, while we demonstrate the effectiveness of anchoring 
palivizumab, other anchored broadly neutralizing antibodies could be encoded in mRNA 
and delivered, representing a promising new tool in the future of viral prophylaxis. 
 Fourth, we found that anchoring antibodies to the plasma membrane limits the 
diffusion of the antibody away from the surface. This effect results in directly increasing 
the clearance time of the antibody away from the target membrane of the pathogen. Half-
lives of broadly neutralizing antibodies are actively being studied, as longer half-lives 
directly result in more sustained protection163. Anchoring the antibody to the membrane of 
interest can increase this half-life, as turnover of the GPI anchored protein is limited by 
cleavage rate (which can be limited as discussed above) and turnover of the membrane, 
which can be slower than transmembrane domain anchored proteins159,164. Dosing size 
and spacing are two aspects of delivery that must be evaluated with regard to mRNA 
expression of anchored antibodies. Though neutralizing antibodies can be quite potent, it 
is unknown exactly how many copies are necessary at the target membrane of a pathogen 
in order to prevent infection. 
 Fifth, we were able to easily encode the GPI anchor onto an RSV-neutralizing 
single domain camelid VHH antibody. The ability to easily adapt the anchor sequence to 
other constructs opens a multitude of new avenues. Not only can the anchor be used for 
VHH antibodies, but also neutralizing single-chain variable fragment (scFv) antibodies, 
which are easily constructed from whole antibodies, allowing for trivial generation of 
prophylactics from newly discovered broadly neutralizing antibodies. The anchor could 




 Finally, we demonstrated that expressing the anchored anti-RSV VHH was highly 
potent at neutralizing RSV infection in mice lungs. VHH antibodies represent a promising 
new tool in passive immunotherapy because they possess high solubility, are one-tenth 
the size of whole immunoglobulins, and have extremely high binding kinetics, reviewed in 
depth by Arbabi-Ghahroudi165. However, the small size of VHHs results in incredibly short 
half-lives, on the order of 30 minutes to a couple of hours126,127. Anchoring VHH antibodies 
to the surface of cells can drastically improve this clearance rate, remedying one of the 
largest problems with single-domain antibody therapeutics. The use of mRNA expressed 
anchored VHH-based antibodies also results in two tangential benefits in that 1) only a 
single mRNA has to be delivered to a cell in order to have a biologically active neutralizing 
antibody (which also increases the number of mRNA copies per unit mass) and 2) smaller 
mRNAs are more efficiently translated due to increased ribosome density, increasing both 
the number of mRNA copies and the amount therapeutic anchored VHH available121. 




 Overall, the work presented here has produced innovative tools to image and 
prevent RSV infections, providing new targets for future antiviral investigations and an 
adaptable new method to inhibit RSV infection in the lung. This work, while answering 
several questions regarding the nature of RSV and mRNA therapeutics, has prompted a 
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